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Liver fibrosis, known to be a consequence of various acute or chronic cellular insults, is a reversi-
ble wound-healing response characterized by fibroblast proliferation and extracellular matrix 
(ECM) remodelling. In particular, fibrosis results from exposure to liver toxicants or chronic liver 
diseases, including viral hepatitis and alcohol consumption. If the injury persists, fibrosis leads to 
portal hypertension, cirrhosis, liver failure, and increased risk of cancer. The development of fi-
brosis involves several intermediate steps, including hepatocyte injury and cell death, oxidative 
stress, activation of Kupffer cells (KC), activation of hepatic stellate cells (HSC), and chronic in-
flammation. Particularly, HSCs have been identified as the primary effector cells of fibrosis, since 
they orchestrate the deposition of extracellular matrix in normal and fibrotic liver. Following liver 
injuries, HSCs trans-differentiate into smooth muscle α-actin (αSMA) positive myofibroblasts-like 
cells in response to several factors released by the other liver cells. Among these factors, trans-
forming growth factor beta 1 (TGF-β1), platelet-derived growth factor (PDGF) and oxidative 
stress, have been shown to play a critical role.  
The present thesis is subdivided into two main projects that focused on the development of a 
suitable model system to study fibrosis and on the role of TGF-β1, PDGF and Nuclear factor E2-
related factor 2 (Nrf2) on HSCs. Currently, most liver fibrosis research is performed in vivo since 
suitable in vitro system are lacking. This is due to short longevity of liver cells in culture and 
inadequacy of cell composition in currently available systems. The first two articles focus on the 
design and development of three-dimensional (3D) in vitro liver fibrosis models: a rat primary cell-
based model and a human cell line based model. For the generation of the rat liver model hepato-
cytes, KC and HSC were isolated from healthy livers whereas the human model contained Hep-
aRG, differentiated THP-1 (macrophages) and immortalized HSCs (hTERT-HSC). These three 
relevant hepatic cell types were cultured in 3D scaffold-free microtissues. The multicellular mod-
els responded to treatment with proinflammatory cytokine TGF-β1 and endotoxin lipopolysaccha-
ride (LPS), displaying hepatocellular damage as demonstrated by decrease in albumin expres-
sion, and HSC activation as demostrated by increased αSMA expression and deposition of ECM. 
In addition, the human model displayed a fibrotic phenotype after exposure to methotrexate (MTX) 
and thioacetamide (TAA), characterized by the activation of HSC, upregulation of genes involved 
in the development of fibrosis and the secretion and deposition of extracellular matrix. MTX and 
TAA also elicited the upregulation of Nrf2 and Kelch-like ECH-associated protein 1 (Keap1) sug-
gesting oxidative defence pathway activation during early stages of fibrosis. This human model is 
able to reproduce key events, generating a clinically relevant fibrotic phenotype. Both systems 
represent suitable cell culture-based alternatives to the widely used animal models for the inves-









The second part of the thesis aimed to elucidate the role of key factors TGF-β1 and PDGF as well 
as the potential role of Nrf2 pathway in HSC activation and to assess the potential of hTERT-HSC 
as an in vitro model to identify these roles. Although many studies have already reported the role 
of both TGF-β1 and PDGF in human HSCs, is not yet clear to which extent they act on the main 
cellular processes that characterize activation, such as proliferation, migration and differentiation. 
The aim of this work was not only to elucidate the effect on these cellular events of each single 
cytokine, but also the effect of the simultaneous exposure to both factors. Upon exposure to TGF-
β1, both primary and hTERT-HSCs activated, differentiating into myofibroblasts-like cells, char-
acterised by αSMA and collagen production. Contrarily, PDGF-AB-treatment did not affect cellular 
activation and fibrogenic capacity, but induced proliferation and cell migration in a concentration-
dependent manner. Simultaneous exposure of HSCs to both factors showed a synergistic effect 
leading to full cell activation, with increases in both proliferative and fibrogenic capacities. The 
results obtained in this study may contribute to the design of novel drugs focused on the inhibition 
of these two key factor in HSC activation as well as to the use of the hTERT-HSC as surrogate 
of primary HSCs. 
Finally, given the crucial role of Nrf2 in maintaining hepatocyte identity and homeostasis as well 
as the evidence showing its involvement in liver fibrosis, identifying its function in HSCs may be 
of relevant therapeutic importance. In this work, activation markers, as well as proliferation and 
migration, were assessed in both human primary and hTERT-HSCs following Nrf2 or Keap1 re-
pression by siRNAs. Knocking down Nrf2 induces αSMA production as well as induction of ECM 
components, clearly indicating an induction of HSC activation. This induced activation was de-
pended on the TGF-β1/Smad pathway, as the two Smad inhibitors SB431542 hydrate and 
SB525334 successfully suppressed the effect of the knockdown. HSC with reduced Nrf2-levels 
also showed an increase in migration and a decrease in proliferation. Moreover, TGF-β1 elicited 
a stronger induction of HSC activation markers in Nrf2 deficient cells than in wild type cells. These 
data point to a novel role of Nrf2 in HSCs, where it acts as a repressive factor for HSC activation 
through the inhibition of the TGF-β1/Smad pathway. This led to the hypothesis that its depletion 
may be a contributing factor to HSC activation and fibrosis. 
In summary, the studies discussed in this thesis deliver contributions addressing two of the limiting 
factors of liver fibrosis research: the lack of a suitable 3D model and the discovery of potential 
pathways on which act in order to revert HSC activation. Firstly, novel and well-suited 3D liver 
models, able to recapitulate the key fibrotic events, were developed. Secondly, the roles of TGF-
β1 and PDGF were further clarified in both primary and hTERT-HSCs. Finally, this thesis de-
scribes a novel role for Nrf2 as a suppressor of HSC activation. The results underlines the im-
portance of the Nrf2 defence pathway, which may play important roles in many cell types and 










2.1 Liver fibrosis and cirrhosis 
Fibrosis and consequent cirrhosis are the end-stages of the perpetuation of the normal wound 
healing response, triggered by chronic liver injury, including chronic viral hepatitis infection, non-
alcoholic steatohepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, cholestasis, in-
born errors and autoimmune liver disease [1,2]. After acute liver injury, liver parenchymal cells 
(i.e. hepatocytes) are able to regenerate and replace the necrotic or apoptotic cells [3]. This pro-
cess is associated with the transient activation of liver non-parenchymal cells (NPCs, i.e. Kupffer, 
endothelial and stellate cells), resulting in an inflammatory response and a limited deposition of 
extracellular matrix (ECM) [3]. However, if the injury persists, liver regeneration fails and chronic 
inflammation and excessive deposition of ECM occur, leading to a progressive substitution of 
hepatic parenchyma by scar tissue [4]. Fibrosis represents the first stage of liver scarring; how-
ever, the accumulation of ECM, extremely enriched in fibrillar collagens (predominantly collagen 
types I and III), distorts the normal liver architecture resulting in pathophysiologic damage to the 
organ [5,6]. The resulting cirrhotic liver is characterized by nodule formation and organ contraction 
with fibrotic septa surrounding regenerating nodules of hepatocytes [6]. The clinical manifesta-
tions of cirrhosis vary widely, from no symptoms at all, to physical and mental symptoms when 
liver damage is extensive [7]. Up to 40% of patients with cirrhosis are asymptomatic and may 
remain so for more than a decade, but the development of complications (including ascites, vari-
ceal haemorrhage or encephalopathy) inevitably induces a progressive deterioration of the liver, 
resulting in a 50% 5-year mortality rate, with approximately 70% of these deaths directly attribut-
able to liver disease [8]. In addition, this condition led to hepatic insufficiency and portal hyperten-
sion with an increased risk for developing hepatocellular carcinoma [9]. Liver fibrosis and cirrhosis 
have a wide geographic distribution and are important causes of morbidity and mortality world-
wide. Global deaths due to cirrhosis have increased since 1980, reaching the 1.95% of the global 
total deaths in 2010 and 1.8 % of total deaths in Europe in 2013 [10,11].  
Currently, no treatments or therapies are available to cure cirrhosis or repair liver scarring that 
has already occurred. The only effective curative remedy is liver transplantation, but this interven-
tion still presents many disadvantages, such as donor organ deficiency, surgical complications, 
immunological rejection, high medical costs and high mortality rate of transplanted patients 
[12,13]. For these reasons, in the last 20 years, there has been an increasing interest in under-
standing the pathogenesis of liver fibrosis in order to identify the main cellular effectors of this 
disease as well as the key cytokines and determinants of ECM turnover involved in the fibrotic 
process. Researchers focused on the development of new therapeutic approaches based mainly 
on cellular model systems, as more convenient tools to study the molecular mechanisms behind 









2.2 Histological organization of liver 
The functional unit of the liver is a well-defined structure known as lobule. When viewed in cross 
section, each lobule presents a hexagonal shape, consisting of linear cords of hepatocytes which 
radiate out from a central vein (Figure 1 a and b) [14,15]. The hepatocytes represent the main cell 
type of the liver, occupying almost 80% of the total liver volume and performing the majority of 
numerous liver functions, such as metabolism, detoxification, storage and bile production [16]. 
Liver NPCs (liver sinusoidal endothelial cells LSEC, Kupffer cells KC, and hepatic stellate cells 
HSC) contribute only to 6.5% to the liver volume, but 40% to the total number of liver cells [16]. 
To carry out all their functions, the hepatocytes form an epithelial-like structure and are in close 
contact to vascular channels called sinusoids, of which the fenestrated walls are lined by LSEC, 
KC and HSC cells [16]. On the apical side of the hepatocytes, tiny bile collection vessels known 
as bile canaliculi run parallel to the sinusoids on the other side of the hepatocytes and drain into 
the bile ducts of the liver [15] (Figure 1 b). Situated around the perimeter of the lobule are 
branches of the hepatic artery, hepatic portal vein (which deliver oxygen and nutrients into the 
blood in the sinusoids) and bile duct. These three ducts cluster together forming the so called 
portal triad at the “corner” of the liver lobule [17]. On the other side of the hepatic epithelium, the 
area between endothelium and hepatocytes, is known as Space of Disse which collects lymph for 
delivery to the lymphatic capillaries [17,18]. The space of Disse also hosts KC and HSC, where 
they are in close contact with both hepatocytes and LSEC (Figure 1 c). Dendritic cells and other 
immune cells are also present in the Space of Disse, containing also ECM components such as 
collagen I and pro-collagen III, non-collagen glycoproteins, glycosaminoglycans, proteoglycans 
and matrix-bound growth factors which play an important role in the regulation of cell function in 
the healthy and fibrotic liver [19,20]. The ECM is in fact an essential histological component of all 
organs, as it can directly influence the function and behaviour of surrounding cells via interactions 
with cell surface receptors (including integrin and non-integrin matrix receptors). It also indirectly 
affects cell function via release of soluble cytokines, which in turn are controlled by local metallo-
proteinases (MMPs) [5]. After liver injury, the space of Disse is the first affected liver region, since 
the HSC are the main ECM producing cells in the normal and injured liver. Hepatic ECM under-
goes a transformation and enrichment of fibrillar components, primarily collagen I and collagen 
III. Similar to other tissues, the fibrotic component of the liver’s wound healing response is medi-









2.3 Cellular pathways involved in stellate cell activation 
HSCs have been recognized as human liver cells for over 100 years, yet HSC function was only 
clarified in recent times. HSCs, which constitute 5-8% of all liver cells, are resident perisinusoidal 
cells in the space of Disse [21,22]. During the last decades, the role of HSCs was thought to be 
restricted in storing vitamin A (approximately 80% of the total vitamin A in the body), and synthe-
sizing ECM components in the normal and fibrotic liver [23,24]. However, HSCs also are important 
sources of paracrine, autocrine, juxtacrine and chemoattractant factors, all characteristics that 
make them critical cells in maintaining microenvironmental homeostasis of the hepatic sinusoid. 
It was reported that they have the capacity to interact with immune cells, and modulate their ac-
tivity or promote their differentiation by releasing cytokines or directly acting as antigen presenting 
cells. Additionally, they can contribute to angiogenesis, hepatocyte regeneration and to the regu-
lation of oxidant stress [22–24].  
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Figure 1. Representation of the histological microstructure of the liver. (a) When viewed in cross section, the 
liver shows a regular organization in hexagonal structures called liver lobule. (b) A more detailed visualization of the 
liver lobule shows the hepatocytes organised in an epithelial layer with the hepatic portal vein and hepatic arteries 
branching among them. (c) Detailed visualization of Space of Disse and sinusoids. The sinusoids are lined by mor-
phologically and phenotypically unique endothelial cells that are characterized by the absence of tight junctions, the 
absence of a recognizable basement membrane and the presence of open fenestrae that are organized into sieve 
plates. The sinusoidal endothelium is interspersed with Kupffer cells and overlies the space of Disse, which contains 
extracellular matrix proteins and hepatic stellate cells. Dendritic cells from the parenchyma exit the liver through the 









After liver injury, the HSCs undergo an activation process, which is referred to as the transition 
from a quiescent vitamin A-rich cell to a highly proliferative and fibrogenic cells. As a result of this 
transdifferentiation event, they acquire motility, contractile and proinflammatory properties 
[23,25]. Activated HSCs are smooth muscle α-actin (αSMA) positive myofibroblasts-like cells and 
are considered the major source of ECM in liver fibrosis [23]. The activation process is temporally 
divided into two different stages: initiation (also called preinflammatory stage) that renders the 
cells responsive to cytokines and other local stimuli, and perpetuation during which the cells main-
tain the activated phenotype and generate fibrosis [5,23].  
During the initiation phase, the earliest changes in the HSC are due to paracrine stimulation by 
all neighbouring cell types, including hepatocytes, LSECs, KCs, platelets and leukocytes. After 
the injury, the hepatocytes undergo apoptosis and consequently release apoptotic fragments, 
which are potent fibrogenic elements [26]. Together with the hepatocytes, KCs and resident nat-
ural killer cells (Pit cells) are the first cells responsive to liver injury, releasing free radicals, intra-
cellular constituent and signalling molecules [27]. In particular, KCs produce large amounts of 
reactive oxygen species (ROS) and tumour necrosis factor alpha (TNF-α), enhancing HSC acti-
vation and collagen production [5]. However, the initial stage of stimulation is the initiation of HSC 
proliferation, which has been mainly attributed to KC-derived transforming growth factor beta 1 
(TGF-β1) and platelet-derived growth factor (PDGF) [23]. Moreover KCs and LSECs secrete 
MMPs that convert the latent TGF-β1 in to an activated pro-fibrogenic form that stimulates HSC 
collagen synthesis [28,29]. In addition, after the injury, leukocytes are recruited to the liver and 
join KCs in producing compounds that modulate HSC behaviour. Neutrophils produce ROS and 
nitric oxide, while lymphocytes Th1 and Th2 release cytokines including TNF-α, interleukin 2 and 
6 [30].  
Differently from the initiation phase, a massive deposition of ECM components characterizes the 
perpetuation phase. In particular, TGF-β1 leads to increased deposition of fibrillar collagens, fi-
bronectin and release of MMPs by HSCs [23]. During the perpetuation phase, HSCs also produce 
TGF-β1 maintaining a positive autocrine loop [31]. TGF-β1 also induces the production of specific 
MMP inhibitor molecules, TIMP-1 and TIMP-2, leading to a net decrease in protease activity and 
therefore an increase in matrix accumulation resulting in complete remodelling of the liver ECM 
[32]. However, beside the matrix remodelling and fibrogenic properties, during the perpetuation 
phase HSCs undergo several other changes in cell behaviour, as proliferation, contractility, and 
chemotaxis [5]. As in the initiation phase, the most potent mitogen factor involved in the prolifer-
ation of HSCs is PDGF. The activation of its signalling pathway leads to stimulation of cell growth, 
but also to changes in cell shape and motility in HSCs [33,34]. In addition, PDGF has been iden-
tified as a chemoattractant molecule, combining its effect with that from the leukocyte chemoat-









shows a more complex regulation pathway, since it involves the interplay of many molecular com-
ponents such as contractile regulatory proteins MLC kinase (MLCK), Rho kinase 2 (ROCK2) and 
endothelin-1. The cytological response to the acquisition of contractile properties is the expres-
sion of αSMA, while the physiological response is the impeded blood flow both by constricting 
individual sinusoids and by contracting the cirrhotic liver in Ca(2+)-dependent manner both in vitro 
and in vivo [36].  
Concurrent with the perpetuation phase, the hepatocytes lose their microvilli and the endothelium 
loses its fenestrae, impairing the rapid bidirectional transport of solutes between sinusoidal blood 
and parenchymal cells [37]. 
2.4 Oxidative stress and liver fibrosis 
Although TGF-β1 is the most potent stimulus of fibrogenesis, it acts together with other factors as 
interleukin-1β, TNF-α and oxidative stress [6,38]. In particular, oxidative stress, understood as an 
intracellular condition of biochemical imbalance between oxidative and reductive reactions to-
wards oxidation, represents a very common link among different modes of persistent liver injury 
[39]. In aerobic life, the generation of ROS (including superoxide O2-, hydroxyl radical HO- and 
non-radical hydrogen peroxide H2O2) is a natural mechanism involved in signal transduction path-
ways, defence against invading pathogens and gene expression to the promotion of growth or 
death [40]. Nevertheless, an excessive amount of ROS is highly toxic to cells, since they affect 
both structure and function of major cellular components: proteins, lipids and DNA [41]. Lipids are 
the main and consistent target of oxidative stress and lipid peroxidation in damaged hepatocytes 
is one of the first key events leading to liver fibrosis [42]. For instance, excessive oxidation of 
polyunsaturated membrane lipids is a key outcome in alcoholic liver diseases, due to the alcohol 
metabolism in the liver [39]. In the hepatocytes, ethanol is degraded through the microsomal sys-
tem catalysed by cytochrome P450 2E1 (CYP2E1), which generates ROS leading to oxidative 
stress and cell death [41]. The conversion of ethanol into acetaldehyde by alcohol dehydrogenase 
in the hepatocytes represents the second metabolic pathway for alcohol. It has been shown that 
acetaldehyde stimulates H2O2 and collagen production by HSC, as well as the up-regulation of 
cytokines triggering an inflammatory response by KCs and LSECs during alcoholic liver diseases 
[43,44]. Acetaldehyde, and in particular its derivative malondialdehyde, was shown to be in-
creased also in the serum of patients with chronic hepatitis [39]. Together with the generation of 
ROS by CYP2E1 activation, a significant increased amount of ROS has been shown to due to 
glutathione (GSH) depletion during cholestasis and drug-induced liver injury [45]. However, ROS 
do not damage the hepatocytes exclusively by these pathways; indeed, oxygen radicals may also 
sensitize hepatocytes to lipopolysaccharide and TNF-α toxicity [41]. The pathological response 
of the liver to severe oxidative stress is hepatocyte apoptosis. Moreover, increasing evidence has 









rodents [46,47]. ROS have been identified as key mediators for the pro-fibrogenic actions on 
HSCs in several studies, by evaluating the role of conditioned medium from hepatocytes and 
LSECs in stimulating HSCs [46,48,49]. For these reasons, the liver constitutes a particularly sus-
ceptible organ to oxidative stress, and it is therefore equipped with special defence mechanisms 
to scavenge ROS [41]. 
2.5 Nrf2 pathway as key regulator of oxidative stress 
In the liver, protective mechanisms against oxidative stress include several enzymes (e.g. super-
oxide dismutase and catalase and glutathione S-transferases GSTs) as well as no enzymatic 
compounds (e.g. tocopherol, vitamin E, beta-carotene, ascorbate and GSH) [50–52]. In many cell 
types, the response to oxidative stress is the induction of a series of antioxidant genes through 
the activation of the antioxidant response element (ARE) as a protective mechanism. Expression 
of genes containing ARE in the promotor region is largely regulated by nuclear factor E2-related 
factor 2 (Nrf2). Its activation affects the enzymes that are responsible for GSH homeostasis, 
NAD(P)H quinone oxidoreductase 1 and UDP-glucosyltransferase [53–55]. Under normal condi-
tions, Nrf2 is an highly unstable protein with a half-life of around 15 minutes, since it is degraded 
in a Kelch-like ECH-associated protein 1 (Keap1)-dependent manner [53,54]. Nrf2 is constantly 
bound by Keap1, an adaptor molecule for the Cullin3-based E3 ubiquitin ligase complex, leading 
to the degradation of Nrf2 via the ubiquitin-proteasome pathway [54]. Elevated levels of ROS and 
electrophiles cause the inactivation of Keap1, resulting in Nrf2 release and stabilization. Nrf2 
translocates into the nucleus and regulates the transcription of a network of genes involved in 
various cellular activities, including redox balance, metabolism, proliferation, and apoptosis (Fig-
ure 2) [56].  
Figure 2. The Nrf2-Keap1 antioxidant pathway. Under constitutive conditions, Nrf2 continuously undergoes pro-
teasomal degradation. Electrophiles, free radicals, or inducers of Nrf2, disrupt the Nrf2-Keap1 association leading to 
a diminished rate of proteolysis, and thereby enhancing nuclear accumulation. Nrf2 binds ARE elements in the pro-
moter region of its target genes and induces a battery of cytoprotective genes and anti-oxidative enzymes resulting 
in an adaptive response (repair and removal of damaged protein, cell survival and reduction of oxidative damage). 









Thereby, Nrf2 has been identified as a multi-organ protector, since its involvement in protecting 
various cell types and is required for maintaining tissue homeostasis by increasing classic ARE-
driven detoxification and antioxidant genes [57]. Nrf2 fulfils many different cellular activities, by 
regulating the expression of over 500 genes, which may be either activated or repressed through 
the ARE element or by transcription factors regulated by Nrf2 [55]. Once in the nucleus, Nrf2 may 
interact with the transcriptional regulators Jun and Fos, leading to the induction or suppression of 
gene transcription, respectively [63,64]. Nrf2 deregulation is a clear hallmark of many human can-
cers. Among other tumours, Nrf2 is elevated in some breast and lung cancer, while its expression 
is suppressed in ovarian serous adenocarcinoma as well as in hepatocellular carcinoma [60–64]. 
In cancers, Nrf2 plays an important role in cell migration, as reported for lung adenocarcinoma 
cells where it induces migration and metastasis via regulating the calcium binding protein S100P 
[65]. High susceptibility to carcinogenesis induced by several carcinogens or inflammation has 
been shown in multiple organ systems in Nrf2-knockout mice [66–68]. In the liver, loss of Nrf2 
expression was associated with increased progression of human hepatocellular carcinomas as 
shown by experiments conducted in transgenic mice [69]. Other studies conducted on animal 
models suggest that the Nrf2 pathway counteracts alcoholic and non-alcoholic liver disease, viral 
hepatitis, fibrosis and cancer by activating gene expression [70]. In particular, an exacerbated 
liver cytotoxicity to acetaminophen (APAP) has been reported in Nrf2-knockout mice, while 
Keap1-knockout mice were significantly more resistant to APAP than control animals [71–73]. In 
a different study, in vivo analysis of murine liver showed an increase in nuclear translocation of 
Nrf2 after APAP administration, suggesting an active role of this pathway in the protection against 
APAP [74]. Nrf2-knockout also strongly aggravated liver damage after treatment with carbon tet-
rachloride or ethanol in a different set of studies in mice [75,76]. These protective effects are in 
part connected to the role that Nrf2 plays in the hepatocytes, where it is a key regulator of the 
constitutive and inducible expression of some phase II and III detoxification enzymes and antiox-
idant proteins, such as those involved in GSH synthesis [77]. In addition, Nrf2 participates in the 
regulation of hepatocyte proliferation as well as in the maintenance of a mature hepatocyte iden-
tity state during liver regeneration [78,79]. Nrf2 regulates the activity of the Cdk1/Cyclin B1 com-
plex, determining the transition from the G2 to M cell cycle phase in the hepatocytes [80].  Nrf2 
also displays an antifibrotic effect on the liver, lung and kidney, by promoting the dedifferentiation 
of fibroblasts [81–83]. It was also suggested that Nrf2 may interact with the TGF-β1/Smad path-
ways in regulating cellular motility and plasticity in many cancer cell types [84]. Thus, studying 
Nrf2 pathway in fibrotic disease, and in particular in relation to TGF-β1, may improve the under-
standing of the role of oxidative stress and enable the design of new antioxidants-based therapies 
against liver disorders. This point is further developed in Chapter 4 of this thesis, focusing more 









 Project 1: 3D models for liver fibrosis 
3.1 Introduction 
Up to now, the most common methods to investigate liver fibrosis and cirrhosis are animal models 
or human liver biopsies [6]. The main two currently used animal models are rodents where fibrosis 
has been induced by carbon tetrachloride treatment or bile duct ligation [85]. However, animal 
systems might not be human-relevant, are costly and subject to ethical problems. In human, he-
patic venous pressure gradient has been recently used clinically for fibrosis diagnosis, risk strati-
fication, preoperative screening for liver resection, and assessing the prognosis of liver fibrosis 
[86]. However, this method does not allow direct analysis on liver tissues, and the most reliable 
method to assess liver fibrosis and cirrhosis remains the use of liver biopsies. Histological exam-
inations as well as staining of ECM components are indeed useful  to understand the stage of 
fibrosis as well as the causes which lead to the disease [6]. Nonetheless, human biopsies present 
many disadvantages, as sampling error or semi-quantitative measurement, as well as being an 
invasive procedure, which implies ethical considerations preventing multiple sampling from pa-
tients for research purposes. Hence, a cell-based model system would be a more convenient tool 
to induce, assess and study the molecular mechanisms during fibrosis development. Cell-based 
assays have been an important pillar for a wide range of basic and clinical in vitro research as 
well as for drug discovery, providing a simple, fast, and cost-effective system to minimize large-
scale and expensive animal experiments [87]. To date, most of cell-based assays use traditional 
two-dimensional (2D) monolayer cells cultured on flat and rigid substrates. However, 2D cell cul-
ture does not adequately reflect the liver situation in vivo, mainly due to the loss of hepatocyte-
specific phenotype and HSC activation in culture [88,89]. In particular, HSCs undergo activation, 
losing their quiescent, vitamin A-storing, phenotype and fully taking on their activated, prolifera-
tive, myofibroblasts-like phenotype within 7 days in culture [90]. For these reasons, there was a 
need of a more physiologically relevant cell culture model to study fibrotic diseases, which led to 
the development of new three-dimensional (3D) culture systems. Differently from 2D models, 
these 3D systems provide the correct cell polarization and cell-cell contacts [91–93]. For decades, 
it has been shown that 3D cultures of rat or human hepatocytes maintain liver-specific function 
for extended culture periods preserving also structural polarity and forming functional bile cana-
liculi [94–96]. Rat HSCs have also shown to partially revert their activated phenotype when cul-
tured in a 3D microenvironment, such as on collagen, Matrigel or Engelbreth-Holm-Swarm tu-
mour-extracted basement membrane gel [89,97]. However, due to the multicellular pathophysiol-
ogy of fibrosis, biologically relevant models to study this disease require functional hepatocytes, 
as well as KC and HSC in a quiescent state and in close spatial interaction. For this reason multi-
cellular models, including primary hepatocytes and primary NPCs, have been developed 
[88,91,98]. In particular, a collagen gel sandwich 3D model with human primary hepatocytes, HSC 









non-alcoholic steatohepatitis in vivo [98]. In another study, a fibrotic 3D-spheroid based on 
hepatocytes and HSC has been developed, but this system lacks macrophages that are involved 
in important steps during the chain of events leading to fibrosis [99]. A different study demon-
strated that cultured liver cells on a 3D scaffold had a preserved composition of hepatocytes, 
HSC, KC and LSEC, and maintained liver function for up to 3 months [92]. However, the suitability 
of this model for the study of fibrosis cannot be assessed, due to the lack of data on fibrotic 
response as well as on changes in ECM after stimulation [92]. Therefore, although the benefit of 
these established models, most in vitro systems are of limited use to address fibrosis, due to short 
longevity in culture, inadequacy of cell composition but especially to high handling complexity 
[92,98,99].  
This chapter of the thesis contains two studies on the development of new rat and human liver 
models. In particular, the first study aimed on the development of a 3D microtissue (MT) including 
rat primary hepatocytes, KC and HSC, as key essential cell types involved in hepatic fibrosis. The 
second and main part of this chapter focused on the development of an analogous model with 
human relevant cell lines representing hepatocyte (HepaRG), macrophages (THP-1) and HSCs 
(hTERT-HSC), in order to develop an alternative model to human primary-based systems. Both 
presented models were generated with the hanging drop method, allowing the production of scaf-
fold-free and size-controlled MTs in a 96-well format. Such systems may be used to investigate 
the pathophysiology of fibrosis, as well as to the identification of new compounds with pro-fibrotic 










3.2 Paper 1  
 
Rat multicellular 3D liver microtissues to explore TGF-β1 induced 
hepatotoxicity and fibrosis in vitro 
 








Aims: Develop a novel 3D rat liver model containing hepatocytes, KC and HSC as key relevant 
cells in hepatic fibrosis.   
Results: The generated model was able to respond to TGF-β1 and LPS, resulting in hepatocyte 
damage, HSC activation and release of cytokines. 
Conclusion: This study showed that the new rat liver model is a powerful system to mimic fibro-



























Liver cirrhosis is the end-stage of several liver diseases, in which 
acute liver damage leads to chronic inflammation and fibrosis (Ire-
dale, 2007). Fibrosis also plays an important role in toxicology, 
and re- presents a distinct adverse outcome pathway (AOP). This 
AOP directly involves three hepatic cell types: The suggested se-
quence of events involves hepatocyte (Hep) injury and death, fol-
lowed by the activation of Kupffer cells (KC) and hepatic stellate 
cells (HSC), leading to chronic inflammation and increased depo-
sition of extracellular matrix (ECM) (Ankley et al., 2010; Horvat 
et al., 2016). Stimuli such as reactive oxygen species (ROS) and 
cytokines such as TNF-α and TGF-β1, lead to HSC activation and 
subsequently to increased deposition of fibrillar components of the 
ECM (Gäbele, Brenner, & Rippe, 2003) (Friedman, 2000). Acti-
vated HSC, in turn, produce more TGF-β1 and potentiate and per-
petuate their activation in an autocrine loop (Arias, Lahme, Leur, 
Gressner, & Weiskirchen, 2002). At this stage several changes in 
cell behaviour occur, such as increases in proliferation, contractil-
ity, fibrogenesis, chemotaxis and release of matrix components.  
Currently, studies of cellular and molecular mediators of liver fi- 
brosis are conducted mainly on experimental animal models 
(Constandinou, Henderson, & Iredale, 2005) (Marques et al., 
2012). The rodent in vivo models of chemically or surgically in-
duced fibrosis have several disadvantages, as they are time-con-
suming and lead to con- siderable animal suffering. Cell culture 
techniques have recently moved from two-dimensional (2D) cul-
tures to more complex three-dimen- sional (3D)-cell cultures, 
that allow long-term culture of multicellular systems. It has been 
shown that a 3D environment supports the main- tenance of hu-
man Hep functions and partially restores a quiescent phenotype 
in rat HSC (Kyffin et al., 2019; Messner, Agarkova, Moritz, & 
Kelm, 2013). In 2016, Feaver et al. published a 3D model with 
human primary Hep, HSC and macrophages in a collagen gel 
sandwich (Feaver et al., 2016). In our laboratory, we have estab-
lished a human 3D co- culture model with human cell lines (Hep-
aRG, THP1 and hTERT-HSC) able to recapitulate in vitro the 
key events of a fibrosis AOP and the effect  of  TGF-β1  on  the  
activation  of  HSC  (Prestigiacomo, Weston,
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A B S T R A C T 
 
 
Chronic liver damage can lead to fibrosis, encompassing hepatocellular injury, activation of Kupffer cells (KC), 
and activation of hepatic stellate cells (HSC). Inflammation and TGF-β1 are known mediators in the liver fibrosis 
adverse outcome pathway (AOP). The aim of this project was to develop a suitable rodent cell culture model for 
the investigation of key events involved in the development of liver fibrosis, specifically the responses to pa- 
thophysiological stimuli such as TGF-β1 and LPS-triggered inflammation. 
We optimized a single step protocol to purify rat primary hepatocytes (Hep), HSC and KC cells to generate 3D 
co-cultures based on the hanging drop method. 
This primary multicellular model responded to the profibrotic cytokine TGF-β1 (1 ng/mL) with signs of he- patocel-
lular damage, inflammation and ultimately HSC activation (increase in αSMA expression). LPS elicited an inflam-
matory response characterized by increased expression of cytokines. 
3D-monocultures comprising only Hep displayed different responses, underlying that parenchymal and non- 
parenchymal cells need to be present in the system to recapitulate fibrosis. The data also suggest that pre- 











Fig. 1. Immunostaining of 2D culture of rat primary liver cells. (A) Hep show a multinucleate phenotype as well as positive staining for albumin 
after fixation at day 4. (B) Immunostaining of rat primary HSC after 7 days and (C) 14 days in culture. Red: desmin; Green: smooth muscle actin 
(αSMA); Blue: nuclei. The pictures show the typical HSC morphology with dendritic structures. After 7 days in culture, cells were positive for desmin 
with some expression of αSMA. After 14 days in culture activated  HSC  produced large  amounts  of αSMA and  started  losing desmin  expression.  
(D) Immunostaining  of  F4/80 in  rat primary Kupffer cells after  7 days in culture. Representative images from 4 different experiments. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
 
Table 1 
Cell numbers after purification from rat liver. Fractions containing 
Hep, HSC or KC obtained from rat livers. Cell viability was deter-
mined using Trypan Blue exclusion staining. The values are ex-
pressed as mean ± SD (N = 10 for Hep; N = 5 for NPCs). 
 
Number of harvested cells Viability (%) 
Hepatocytes 32 × 106 ± 1.6 × 106 93.4 ± 1.65 
Stellate cells 26 × 106 ± 1.38 × 106 85.6 ± 2.8 
Kupffer cells 34 × 106 ± 1.26 × 106 89.2 ± 2.4 
 
Messner, Lampart, & Suter-Dick, 2017). Several other researchers 
de- veloped co-culture models aiming to reproduce the hepatic mi-
cro- environment, but often these models underrepresent non-paren-
chymal cells (NPCs), and/or required the use of growth factors 
(Kostadinova et al., 2013; Lauschke, Hendriks, Bell, Andersson, & 
Ingelman- Sundberg, 2016; Leite et al., 2016; van Grunsven, 2017). 
However, a more physiological rat co-culture model to facilitate in 
vivo-in vitro comparisons within the same species is still lacking, 
despite of rat being a common model for the study of liver fibrosis. 
In this work, we set off to establish a primary co-culture system with 
primary rat hepatic cells. We included parenchymal (Hep), as well 
as non-parenchymal (KC and HSC) co-cultured as multicellular, 
3D-microtissues (MTs). We chal- lenged the in vitro system with 
pathophysiological stimuli that are key in the development of 
inflammation and liver fibrosis (LPS and TGF-β1), and were able 





































Fig. 2. TNF-α release after LPS-treatment of 2D cultures of rat 
primary Kupffer cells. At 48 h, LPS induced TNF-α release by 
KC; produced TNF-α was pro- portional to the number of 
KC/well. Mean ± SD of 6 replicates. 
 
2. Material and methods 
 
2.1. Isolation and enrichment of primary rat hepatic cells 
 
Fresh rat primary liver cells were kindly provided by Dr. Franziska 
Boess (F. Hoffmann-La Roche, Basel). Cells were obtained from 
200 to 300 g adult male Wistar rats by a two steps collagenase per-
fusion (Berry & Friend, 1969; Göldlin & Boelsterli, 1991). Total 
liver cells were fractioned in a Hep-rich fraction (sediment) and a 
NPC fraction (sus- pension). Further enrichment of HSC cells and 
KC from the NPC fraction was achieved by means of a discontinu-
ous Nycodenz (Axon lab; Cat. 1,002,424) gradient in Gey's Bal-



























Fig. 3. Immunohistochemical detection of cell-type specific markers. MTs consisting of Hep-monocultures (A, C, E and G) or co-cultures (B, D, F 
and H) were kept in culture during 14 days before performing histological staining. Positive staining for vimentin, αSMA and CD68 was detected in 
co-culture tissues (D, F and H). Hep- monoculture did not express these NPC-markers, with exception of two potentially misplaced MTs in panel G 
(* smaller size and CD68-positive cells). The αSMA-stain was not very prominent (arrow, panel F) as activation of HSC had not been induced. 






























The gradient consisted of three Nycodenz layers: 16.10% 
Nycodenz (density 1.09 g/mL); 12.27% Ny- codenz (density 
1.07 g/mL) and 8.43% Nycodenz (density 1.05 g/mL) layered 
underneath 8 mL of the NPC fraction. After centrifugation at 
1′500 ×g for 17 min at 4 °C, HSC were harvested from the 1.05 
g/mL Nycodenz phase and the interface just above. KC were har-
vested from the interface between 1.07 g/mL and 1.09 g/mL. Af-
ter washing, cell vitality was determined using Trypan Blue 
(Sigma; Cat. T8154) exclu- sion stain, and lipids in the HSC 
were visualized with UV light. Unless stated otherwise, cells 
were cultured in complete medium: DMEM High Glucose (Cat. 
41,965) and Fetal Bovine Serum (FBS) (Cat. 10,270), purchased 


























Cat. A8943). For some experiments, HSC were pre-activated by 
culturing for 2 weeks on plastic (identified as HSC*); KC were 
pre- activated by exposure to 2 μg/mL LPS for 48 h prior the 















Fig. 4. Cell viability after exposure to LPS and TGF-β1. Effect of 14 
days ex- posure to LPS and TGF-β1 on the viability of rat liver of MT 
consisting of Hep-monocultures (Hep), co-cultures (Hep/KC/HSC) and 
co-cultures generated with pre-activated NPCs (Hep/KC*/HSC*). (A) 
MTT-viability assay and (B) LDH activity in the medium collected over 
14 days and analysed as a pool. Values are expressed as mean ± SD 
of 2 (Hep) or 3 (Hep/KC/HSC) cell isolations with 4 technical replicates 
each. 
 
2.2. Generation and treatment of microtissues 
 
All MTs were generated using the GravityPLUS™ Hanging Drop kit 
from InSphero (Schlieren, Switzerland; Cat. ISP-06-001), follow-
ing provider's instructions. Each rat MT was generated with 2′000 
Hep alone or 1′000 Hep + 500 KC + 500 HSC. After four days, all 
MTs were transferred to GravityTRAP™ plates. 
Exposures of MT to LPS (Sigma; Cat. L3129; 2 μg/mL) or TGF-
β1 (Sigma; Cat. T5050; 1 ng/mL) were conducted for 14 days on 4 
MTs pooled into one well; medium was refreshed every other day. 
 
2.3. Viability assays 
 
Cell viability was assessed either by MTT-assay or by measuring 
LDH-leakage into the medium. Briefly, 0.5 mg/mL MTT (3-(4,5-
di- methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
added to 4 MTs pooled into one well and incubated at 37 °C for 4 h. 
After addition of DMSO and Sörensen buffer, the absorbance was 
measured at 550 nm with the FlexStation 3 Reader. LDH activity in 
the medium was mea- sured with Cytotoxicity Detection KitPlus 
(Sigma; Cat. MAK066) ac- cording to manufacturer's instructions. 
Cell supernatant was collected periodically over 14 days and com-
bined before analysis. Absorbance at 450 nm was measured on a 
FlexStation 3 Reader. 
 
2.4. Immunostaining 
Monolayer cultures and MTs were fixed in 4% paraformaldehyde 
(PFA) for 15 min and 60 min, respectively. 2D and 3D-cultuers 
were permeabilized with 0.1% Triton-X-100 for 20 min and 60 
min, respec- tively. MTs were immobilized in 2% agarose before 
embedding in paraffin. Staining of fixed monolayer and 3D cul-
tures was performed following standard protocols using the fol-
lowing primary antibodies: Albumin (Abcam Ab53435), α-
smooth muscle actin (αSMA) (Sigma, A5228), Desmin (Thermo 
Fisher, Cat. RB-9014-P), F4–80 (Abcam, Ab74383), Vimentin 
(Abcam, Ab92547). Alexa Fluor® 488 F(ab’)2 Fragment of Goat 
Anti-Mouse IgG (H + L) (Invitrogen, Cat. A11017) and Alexa 
Fluor® 546 F(ab’)2 Fragment of Goat Anti-Rabbit IgG (H + L) 
(Invitrogen, Cat. A11071). For histological slides of the MT, fol-
lowing primary antibodies were used: Vimentin (Epitomics, Cat. 
2707–1), αSMA (Sigma, Cat. F3777), CD68 (Novacastra Labora-
tories, cat. NCL-L- CD68). 
 
2.5. Gene expression analysis 
 
RNA was isolated from 4 MTs pooled into one well following a 
TRIzol standard extraction procedure. Real time, Taqman qPCR 
was performed following standard protocols and using commer-
cially available primers/probes: Albumin (Invitrogen, Cat. 
Rn00592480_m1), αSMA (Invitrogen, Cat. Rn01759928_g1), 
TGF-β1 (Invitrogen, Cat. Rn00572010_m1), Interleukin 6 (IL6) 
(Invitrogen,  Cat.  Rn01410330_m1) and TNF-α (Invitrogen, Cat. 
Rn01525859_g1). The cycle threshold values were assessed using 
the Corbett Rotorgene Analysis Software 6000 and 18SRNA (Invi-
trogen, Cat. Rn01428913_gH) was used as an internal standard for 




The presence of TNF-α in the supernatants of treated samples was 
determined using a commercial ELISA kit (Invitrogen, Cat. 
KRC3012). 
 
2.7. Statistical analysis 
 
Data were analysed using GraphPad Prism 7 (GraphPad Soft-
ware, inc.) and expressed as mean values ± standard deviation 
(SD). The Student's t-test was used for comparison between two 
groups. Data from three or more groups were analysed by one-
way analysis of variance with Tukey's multiple comparisons 
test. P ≤ .05 was considered sig- nificant and depicted as fol-




3.1. Rat primary liver cell characterization and microtissue 
generation 
Cells freshly collected from rat livers were partially purified using 
a Nycodenz gradient into three main populations in a reproducible 
manner (Table 1). Primary Hep showed a multinucleated pheno-
type and positive staining for albumin (Fig. 1A). HSC appeared as 
round cells containing lipid droplets, spread during 2–4 days in cul-
ture. At day 7 in culture they displayed the typical HSC morphol-
ogy, expressing desmin and low levels of αSMA (Fig. 1B). With 
prolonged culture times, HSC became activated, were larger, ex-
pressed less desmin and stained po- sitive for αSMA. After 14 days 
in culture, the activated HSC appeared as a homogeneous popula-
tion of highly proliferating cells expressing αSMA arranged in 
stress fibres (Fig. 1C). Enriched KC displayed the morphology of 
adherent, dendritic-type cells that expressed F4–80 glycoprotein 
(Fig. 1D), and produced TNF-α upon stimulation with LPS (Fig. 2). 
 Liver MT preparation with rat primary cells yielded 100% size- 
controlled MTs with an average diameter of 350 μm for co-cul-
tures and 250 μm for Hep-monoculture MTs. Assessment of MT 
composition confirmed that co-culture MTs contained both Hep 
and NPCs, as determined by pre-staining with CellTracker dyes 
(data not shown) and immunohistochemistry of the NPC markers 
Vimentin, αSMA and CD68 (Fig. 3). Necrotic cores were observed 













Fig. 5. Transcriptional responses of co-culture MT (Hep/KC/HSC) to pro-inflammatory (LPS) and pro-fibrotic (TGF-β1) stimuli. The following genes 





3.1. Response of rat liver microtissues to treatment with LPS 
and TGF-β1 
Rat liver MTs were stimulated with LPS and TGF-β1 to assess the 
cellular responses of Hep-monoculture and co-culture systems. In 
Hep- monoculture MTs TGF-β1 (1 ng/mL) induced a decrease in 
viability that was not observed when NPCs were present. This was 
determined by a reduction of formazan formation in the MTT assay 
and an increase in LDH-leakage into the medium (Fig. 4). In co-
cultures exposed to LPS and  TGF-β1,  gene  expression  of  
specific  HSC-activation  and  inflammatory  markers  (i.e.  αSMA,  
TGF-β1,  TNF-α,  and  IL-6)  was increased while albumin expres-
sion was strongly reduced (Fig. 5). 
Immunostaining further demonstrated the activation of NPC, as as-
sessed by increase in vimentin- and αSMA-positive cells in co-cul-
tures treated with TGF-β1 (Fig. 6B). This was not observed in Hep-
mono- culture (Fig. 6A), which showed the expected low levels of 
both vi- mentin and αSMA-positive cells. In co-cultures containing 
pre-activated NPCs, vimentin was highly expressed before stimula-
tion and its ex- pression was further enhanced by TGF-β1. Interest-
ingly, pre-activated NPCs in MTs showed low basal expression of 
αSMA but were still able to respond to TGF-β1 with overexpres-




In this study, we have established a rat 3D-liver culture system 
based on parenchymal (Hep) and non-parenchymal (KC and HSC) 
rat primary cells. We utilized this system for studying the cellular re-
sponses to pro-inflammatory and pro-fibrotic stimuli in vitro. 
As a first step, we optimized the isolation of hepatic cell types from 
fresh rat livers. The enriched cell fractions expressed cell-type 




F4–80 for KC and αSMA for activated HSC. NPCs also responded to 
pro-inflammatory and pro-fibrotic stimuli (LPS and TGF-β1, re-
spectively). 
As depicted in Fig. 1C and in agreement with previous reports, the 
HSC underwent activation upon culture for 14 days on plastic (Mas-
chmeyer et al., 2011). This activation was characterized by high ex-
pression of αSMA, a decrease in lipid content and desmin expres-
sion accompanied by mor- phological changes (Olsen et al., 2011). 
After 7 days in culture, en- riched KC were positive for vimentin 
(NPC marker) and macrophage glycoprotein F4–80, a known KC 
marker (Kinoshita et al., 2010). These cells also showed the ability 
to produce and release TNF-α after chal- lenge with LPS.  
As expected, MTs consisting of monocultures (Hep-monoculture) or 
co-cultures (Hep/KC/HSC) behaved differently. Monocultures 
showed a necrotic core that was not noted in the co-culture MTs. 
They also appeared to be more sensitive to TGF-β1-induced cyto-
toxicity (Figs. 4 and 6). There results suggest that a monoculture 
model, consisting of only Hep, can not be used as model system to 
access drug toxic effects in a physiological way. Moreover, our re-
sults show that multicellular MTs may be more stable, probably due 
to improved physiological cell-cell interactions. NPCs are known 
to produce several cytokines that protect the Hep against the TGF-
β1-induced apoptosis (Cosgrove et al., 2008; Ikeda et al., 1996; Kim 
et al., 2000; Rolfe, James, & Roberts, 1997), but our data do not 
allow to identify specific factors. We could however demonstrate 
that NPCs in our system were able to produce cytokines that 
changed  cell phenotypes in the 3D-co-cultures:  The expression of 
TNF-α, IL6 and TGF-β1 were upregulated in KC upon stimulation 











Fig. 6. Immunohistochemical detection of HSC-activation after treatment of co-cultures with TGF-β1 for 14 days. Co-culture MTs showed an increase 
in the vimentin and αSMA-positive cells after TGF-β1 exposure (see arrows). Panel A: Hep; Panel B: Hep/KC/HSC; Panel C: Hep/KC*/HSC*. Naïve 
(B) and pre-activated (C) HSC show low basal αSMA-expression but can both be activated by TGF-β1. Activated HSC seem to locate to the periphery 
of the MTs. Positive staining is shown in brown, while nuclei staining (Haematoxylin) in blue. Pictures taken with 10× and 40× magnification. (For 









response (increase of IL6 synthesis), concomitant with a detri-
mental effect on Hep (decrease in albumin expression). Moreover, 
the levels of αSMA mRNA were strongly increased after LPS and 
TGF-β1 exposure in- dicating activation of the HSC cells. TGF-β1-
treatment induced its own gene expression indicating the onset of its 








TGF-β1 also led to the proliferation of NPCs in the MTs, as estab-
lished by an increase of vimentin-positive cells.In the context of he-
patic fibrosis, our results using primary rat MTs also recapitulate 
some of the key events described as part of the AOP (Horvat et al., 
2016). We could detect a decrease in albumin expression, indicating 
primary hepatocellular damage. We were also able to elicit the acti-
vation of KC by treatment with the known TLR4-ligand LPS, as 










Supplementary Fig. 1. Immunostaining for αSMA and desmin in rat liver microtissues. MTs were generate with fresh isolated Hep and pre-activated 
NPCs, and  stained one week after seeding. Desmin staining shows the presence of HSC in the MTs. However, not all the HSC were positive for αSMA 
staining, which is observed only at the surface of the MTs. Green: smooth muscle actin; Red: desmin; Blue: nuclei. Pictures were taken using 












































Finally, we could reproduce the TGF-β1-induced activation of HSCs 
determined as enhanced expression αSMA. As expected, Hep-mon-
oculture MT failed to display such responses, further supporting the 
need of the intercellular interplay of Hep and NPCs in order to have 
a biological relevant fibrotic model.The influence of a more organ-
otypical culture system on the cell phenotype is further supported by 
the behaviour of pre-activated HSC (HSC*). 
Our preliminary results suggest that HSC* may revert to a more qui-
escent phenotype in the MT; the levels of αSMA change from high, 
widespread expression after pre-activation in 2D (Fig. 1) to low, 
scarce expression after incorporation of these HSC* into the 3D-
MTs (Fig. 6C). We can exclude that this was an artefact due to a 
lack of HSC* in- corporation into the 3D MTs, since the presence of 
HSC in these MT was demonstrated by co-staining with desmin 
(Supplementary Fig. 1) and by the “re-activation” to αSMA-posi-
tive cells after 14 days of  exposure to TGF-β1 (Fig. 6C). Based 
on the presented results and additional unpublished data, the self-
assembly of the MT follows a rather con- sistent pattern, with the 
αSMA-positive, activated HSC in the periphery. The reason for the 
localization of αSMA-positive HSC cells cells predominately to 











































gation. Further studies would be a lso necessary to elucidate the 
molecular and cellular processes, which may be involved in the ob-
served “de-activation” of HSC. Despite these cells being con- sis-
tently activated upon culture on 2D-plastic dishes as depicted in 
Fig. 1C and consistent with published results (Maschmeyer et al., 
2011), we did not observe activated HSC under  basal  conditions  
in  MT (Fig. 6C), which leads us to speculate that the 3D-, co-cul-
tures drive the HCS towards a more quiescent phenotype. 
3. Conclusion 
 
In conclusion, MTs containing three primary hepatic cells (Hep, 
KC and HSC) are able to recapitulate key events in the liver fibrosis 
AOP, in particular hepatocellular damage, inflammatory responses 
and HSC- activation. Hep-monoculture MTs did not show this phe-
notype, in- dicating that the interplay of parenchymal and NPC 
plays indeed a key role. In addition, our data suggest that different 
cell types in co-culture influence the responses of other cell types. 
On the one hand, the pre- sence of NPC made the MTs more re-
sistant to toxicity caused by LPS and TGF-β1. On the other hand, 
pre-activated HSC may reverse to a quiescent phenotype in 3D co-
cultures. 
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Pro-fibrotic compounds induce stellate cell activation, ECM-remodel-
ling and Nrf2 activation in a human 3D-multicellular model of liver     
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Aims: Develop a novel 3D liver cell line based model containing hepatocytes, KC and HSC as 
key relevant cells in hepatic fibrosis.   
Results: The generated model was able to respond to proinflammatory cytokines (LPS, TNF-α, 
TGFβ1) as well as pro-fibrotic cytokines (MTX, TAA) resulting in hepatocytes damage, HSC acti-
vation and collagen deposition. 
Conclusion: This study showed the ability of this new human liver model to recapitulate all the 
key events leading to fibrosis after drug injury.
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   Abstract 
 
Background & Aims 
Currently most liver fibrosis research is performed in vivo, since suitable al-
ternative in vitro systems which are able to recapitulate the cellular events 
leading to liver fibrosis are lacking. Here we aimed at generating a system 
containing cells representing the three key players of liver fibrosis (hepato-
cyte, Kupffer cells and stellate cells) and assess their response to pro- fi-




Human cell lines representing hepatocytes (HepaRG), Kupffer cell 
(THP-1 macrophages) and stellate cells (hTERT-HSC) were co-cultured 
using the InSphero hanging drop technol- ogy to generate scaffold-free 3D 
microtissues, that were treated with pro-fibrotic compounds (TGF-β1, 
MTX, TAA) for up to 14 days. The response of the microtissues was evalu-
ated by determining the expression of cytokines (TNF-α, TGF-β1 and IL6), 
the deposition and secre- tion of ECM proteins and induction of gene ex-
pression of fibrosis biomarkers (e.g. αSMA). Induction of Nrf2 and Keap1, 
as key player of defence mechanism, was also evaluated. 
 
Results 
We could demonstrate that the multicellular 3D microtissue cultures 
could be maintained in a non-activated status, based on the low expres-
sion levels of activation markers. Macro- phages were activated by stim-
ulation with LPS and hTERT-HSC showed activation by TGF- β1. In addi-
tion, MTX and TAA elicited a fibrotic phenotype, as assessed by gene-
expression and protein-deposition of ECM proteins such as collagens 
and fibronectin. An involvement of the antioxidant pathway upon stimula-
tion with pro-fibrotic compounds was also observed. 
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Here, for the first time, we demonstrate the in vitro recapitulation of key molecular and 
cellu- lar events leading to liver fibrosis: hepatocellular injury, antioxidant defence re-





Liver fibrosis and cirrhosis are canonical endpoint of many chronic liver diseases, 
including virus infections (HBV, HCV), non-alcoholic steatohepatitis or damage due 
to alcohol con- sumption [1]. In addition, liver fibrosis is also a relevant toxicological 
outcome and has been identified as an Adverse Outcome Pathway (AOP), a novel 
tool in human risk assessment designed to provide mechanistic representation of 
critical toxicological effects [2,3]. Liver fibrosis is characterized by an accumulation 
of fibrillar extracellular matrix (ECM), leading to liver failure, portal hypertension, and 
increased risk of cancer. The pathophysiology of fibrosis requires chronic liver dam-
age (including chronic alcohol consumption, chemically-induced hepatocyte dam-
age, and viral infections) and involves the interplay of several hepatic cell types; it 
requires hepatocyte injury and cell death, activation of Kupffer cells (KC), activation 
of hepatic stellate cells (HSC), and chronic inflammation [4,5]. 
Hepatic stellate cells, activated by fibrogenic cytokines (e.g. TGF-β1 and TNF-α), have 
been identified as the major collagen-producing cells in the injured liver. Stimuli initi-
ating stellate cell activation derive from injured hepatocytes and neighbouring KC. 
Upon hepatocyte injury, activated KC produce large amounts of reactive oxygen spe-
cies (ROS) and release cytokines such as TNF-α, TGF-β1, PDGF and IL1β, leading 
ultimately to stellate cell activation and increased deposition of fibrillar components of 
the ECM [4–6]. Activated stellate cells, in turn, produce more TGF-β1 and potentiate 
and perpetuate their activation in an autocrine loop [7]. 
It is well documented that liver diseases including hepatitis, fibrosis, cirrhosis, and 
hepato- cellular carcinoma induce antioxidant stress response [8]. Oxidative stress 
also contributes to the release of pro-fibrogenic growth factors, cytokines and pros-
taglandins that may lead to liver fibrosis and/or cirrhosis [8]. Nrf2 (NF-E2-related 
factor-2) is an essential transcription factor that regulates an array of detoxifying 
and antioxidant defence and is finely regulated also by its interaction with Keap1 
[9]. Yang et al. showed up-regulation of Keap1 and Nrf2 mRNA and protein in liver 
tissues of CCl4-induced fibrosis of rat compared with tissues of wild type animals 
[10]. 
Emerging anti-fibrotic therapies aim at inhibiting the accumulation of fibrogenic cells 
and/or preventing the deposition of ECM proteins [4]. The advances in the research 
of anti- fibrotic therapies are however hampered by the lack of appropriate in vitro 
systems for the study of liver fibrosis. Until now, the majority of the investigations on 
liver fibrosis are still per- formed in rodents that underwent chemically-induced fibro-
sis [11]. These animal models have the advantages of providing the physiological 
relevance, but with the strong disadvantages of being time consuming, expensive 
as well as non-human. The efficient development of anti- fibrotic drugs will therefore 
strongly depend on the availability of a suitable in vitro system that more faithfully rep-
licates the pro-fibrogenic microenvironment of human liver [5]. 
Biological relevant models to study liver fibrosis require functional hepato-
cytes, as well as KC and HSC in a quiescent (non-activated) status and in 
close spatial interaction. Three- dimensional (3D) cell culture systems ap-
pear to outperform conventional cell cultures with regards to their metabolic 
activity and responses to toxicants [12,13]. Several methods have 
 
  
manuscript. This does not alter our adher-
ence to PLOS ONE policies on sharing data 
and materials. 
Competing interests: The authors declare that 
they have no conflict of interest that may 
have influenced the data generation or inter-
pretation. 
Abbreviations: AOP, Adverse outcome path-
way; ATP, Adenosine triphosphate; BSA, Bo-
vine serum albumin; CD44, Cluster of Differen-
tiation 44; CD68, Cluster of Differentiation 
68; Col1α1, Collagen 1 alpha 1; Col1α2, 
Collagen 1 alpha 2; Col4α1, Collagen 4 
alpha 1; DMSO, Dimethyl sulfoxide; ECM, 
Extracellular matrix; FBS, Fetal bovine serum; 
GOI, Gene of interest; H&E, Haematoxylin 
and eosin stain; HBV, Hepatitis B virus; HCV, 
Hepatitis C virus; HSC, Hepatic stellate cells; 
IL1β, Interleukin 1 beta; IL6, Interleukin 6; KC, 
Kupffer cells; Keap1, Kelch-like ECH-asso-
ciated protein 1; LPS, Lipopolysaccharide; 
MMP2, Metalloproteinase 2; mRNA, messen-
ger RNA; MT, Microtissue; MTX, Methotrex-
ate; Nrf2, Nuclear factor E2-related factor 2; 
PBS, Phosphate buffer saline; PCR, Polymer-
ase chain reaction; PDGF, Platelet-derived 
growth factor; PFA, Paraformaldehyde; 
ROS, Reactive oxygen species; SD, Stand-
ard deviation; S.E.M., Standard error of the 
mean; TAA, Thioacetamide; TGF-β1, Trans-
       
     
   
 
29 
Hepatic fibrosis in an in vitro 3D-multicellular model 




been published for the generation of scaffold-free liver MT; however, 
these systems are gener- ally based on primary cells and often un-
derrepresent non-parenchymal cells [14,15]. Also, most in vitro liver 
models are of limited use due to short longevity in culture, inadequacy of 
cell composition and/or high handling complexity [13,14,16–18]. Re-
cently, work on a fibrotic 3D-model based on hepatocytes and HSC has 
been published, but this system lacks macro- phages as a key compo-
nent in the chain of events leading to fibrosis [18]. A suitable in vitro 
model for the study of liver fibrosis should mimic processes that involve 
the relevant cell types (hepatocytes, KC and HSC) leading to the devel-
opment of the fibrotic phenotype. Such a sys- tem would be a major asset 
for the understanding of the pathophysiology of fibrosis, as well as for the 
experimental evaluation of substances with regards to the pro-fibrotic 
and anti-fibrotic potential. 
Here, we aimed at investigating liver fibrosis mechanisms in a novel 
human hepatic micro- tissue (MT) model that responds to pro-fibrotic 
stimuli in a similar way to what is known to occur in the human liver. To 
this end, we utilized human relevant cell lines representing the hepato-
cyte, the KC and the HSC. With this system, we could not only recapitu-
late HSC- and KC activation and other key molecular events implicated in 
fibrosis, but also the deposition of ECM in vitro. Our results show that 
methotrexate (MTX) and thioacetamide (TAA), two well characterized 
compounds that cause hepatic fibrosis in animals and man [19, 20] elic-
ited the fibrotic phenotype in vitro. This system can thus be used for the 
investigation of cellular and molecular events involved in the development 
of fibrosis as well as an in vitro test system for the evaluation of anti-fi-
brotic therapies. 
Material and methods 
Reagents and chemicals 
Cell culture media for HepaRG cells were purchased from Biopredic. 
DMEM High Glucose (Cat. 41965) and Fetal Bovine Serum (FBS) (Cat. 
10270) were purchased from Invitrogen. Pen- icillin-Streptomycin (Cat. 
A8943) used for cell culture was purchased by AppliChem). LPS (Cat. 
L3129), TNF-α (Cat. SRP3177), TGF-β1 (Cat. T5050), Thioacetamide 
(TAA) (Cat.163678) and Methotrexate (MTX) (Cat. M8407) were pur-
chased from Sigma. 
Human cell lines 
HepaRG cells were obtained from Biopredic International (Rennes, 
France). The cells were seeded at 1 x 105 undifferentiated cells/cm2 in 
ADD710 Growth Medium Supplement (Biopre- dic). The cells were cultured 
at 37˚C under 5% CO2 for 14 days before differentiation. After 14 days of 
culture, cell differentiation was induced with ADD720 Differentiation Medium 
Supple- ment (Biopredic) for 14 days. Then the cells were maintained for up 
to 4 weeks. 
hTERT-HSC were kindly provided by Dr. Bernd Schnabl (UC San Di-
ego, USA) [21] and were cultured in DMEM High Glucose supplemented 
with 10% FBS and 1% Penicillin-Strep- tomycin. The cells were kept in 
the humidified incubator at 37˚C with 5% CO2. 
THP-1 monocytic cells (Cell Line Service) were cultured at 2–10 x 105 
cells/mL in RPMI 1640 containing 10% FBS, 1% Penicillin/Streptomycin 
and maintained at 37˚C under 5% CO2. THP-1 cells were differentiated 
into macrophages over 48 hours in RPMI 1640 medium containing 5–25 
ng/mL PMA, according to a previously published method [22]. The super-
natants were then removed and the wells were washed with fresh me-
dium. Successful differentiation was assessed by the ability of the cells to 
secrete cytokines upon exposure to 1 μg/mL LPS for 48h. 
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Monolayer cultures of hTERT-HSC were fixed in 4% paraformaldehyde 
(PFA) for 15 minutes, followed by permeabilization with 0.1% Triton-X-100 
for 20 minutes. Blocking was performed with 1% BSA in PBS for 60 minutes 
and washing with PBS; all steps were performed at RT. Pri- mary antibody 
against αSMA (Sigma, A5228, dilution 1:200) and secondary antibody 
Alexa Fluor1 488 F(ab’)2 Fragment of Goat Anti-Mouse IgG (H+L) (Invitro-
gen, A11017, dilution 1:400) were used for the staining. 
Generation of microtissues 
All microtissues (MTs) were generated using the GravityPLUS™ Hang-
ing Drop System from InSphero (Cat. ISP-06-001). Briefly, 40 μL cell sus-
pension/well were pipetted in a 96-well-for- mat GravityPLUS™ plate that 
has been designed specifically to generate reproducible hanging drops. In 
this system, cells are allowed to assemble themselves in a scaffold-free 
manner form- ing spherical MTs. After 2–3 days incubation, MTs are trans-
ferred to 96-well GravityTRAP™ plates, were they can be maintained in 
culture over several weeks. Human liver MTs were gen- erated using 
2’000 cells per MT, with either HepaRG-cells (hepatocyte monoculture), 
or HepaRG in combination with THP-1 and hTERT-HSC. Cell-ratios were 
empirically chosen to give the best resemblance of the native cellular dis-
tribution in liver, approximately 80% hepa- tocytes and 20% NPCs (in-
cluding inflammatory cells and stellate cells), as assessed by immuno-
histochemistry. 
Pharmacological stimulation of microtissues 
For functional characterization, the generated MT were exposed to LPS 
(2 μg/mL), TGF-β1 (1 ng/mL), or TNF-α (50 ng/mL). Further, MTs were 
exposed to the pro-fibrotic compounds MTX (30–250 μM) and TAA (10–
80 mM). The supernatants were collected for protein analy- sis and the 
MTs were used for viability assay (MTT and ATP), mRNA extraction or 
immuno- histological analysis. 
Immunohistochemistry 
MTs were fixed with 4% PFA 1h in PBS containing calcium and magne-
sium. Fixed microtis- sues were embedded in 2% agarose in PBS. The 
samples were subjected to paraffin embed- ding, cut and analysed with 
standard procedures. Microtissues were stained with standard hematox-
ylin & eosin (H&E) and for immunohistochemistry with the following anti-
bodies: albumin (BETHYL Laboratories INC, Cat. A80-229A), Ki67 (No-
vocastra Laboratories, Cat. NCL-L-Ki67-MM1), vimentin (Epitomics, Cat. 
2707–1), αSMA (Sigma, Cat. F3777), Colla- gen I (Abcam, Cat. 
ab88147) and CD68 (Novacastra Laboratories, Cat. NCL-L-CD68). 
Quantification of immunohistochemistry staining 
Five random areas from each immunohistochemistry (IHC) specimen 
were selected. Staining intensity on each image file was assessed by 
using the IHC Toolbox on the image analysing software NIH ImageJ (ver-
sion 2.0.0-rc-56/1.51h). Two different colour segmentations were used: 
one recognized brown-positive cells and the other blue-positive area (nu-
clei). Integrated optical density was obtained as total number of brown 
pixels multiplied by the brown intensity of those pixels, and quantitative 
IHC staining value (QISV) was calculated as integrated optical density 
divided by total area occupied by the brown (positive cells to the staining) 
and blue cells (total cell number) [23]. 
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Cell viability assay 
The viability of the microtissues was assessed by using the Cell-Titer 
Glo1 Luminescent Cell Viability Assay 2.0 (Promega), following stand-
ard laboratory procedures. 
For some MTs the viability was also determined by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphe- nyltetrazolium bromide (MTT) assay. Briefly, 0.5 
mg/mL MTT solution in medium was added to each well and incubated at 
37˚C for 4 hours. The medium was then replaced by 89 μL DMSO, incu-
bated on a shaker for a few minutes; 11 μL Sörensen buffer was added to 
each well and the absorbance was measured at 550 nm. 
Gene expression analysis 
mRNA was isolated following TRIzol extraction procedure. RNA was re-
verse transcribed using a reverse transcriptase (Promega) and oligo dT 
(Qiagen) and real time PCR was per- formed using FastStart TaqMan 
Mix (Roche) and TaqMan probes from Invitrogen. Real time, TaqMan 
PCR was performed on selected genes (Col1α1, Col4α1, fibronectin1, 
CD44, IL6, TGF-β1, αSMA, Nrf2 and Keap1) (see Table 1). The following 
qRT-PCR Program was used: 10 minutes denaturation at 95˚C, followed 
by 40 cycles of 15 seconds at 95˚C and 1 minute at 60˚C. The Ct values 
were assessed using the Corbett Rotorgene Analysis Software 6000 and 
actin was used as an internal standard for the normalization of the fold 
changes of each gene of interest (GOI). 
ELISA 
The presence of cytokines (TNF-α) and extracellular matrix compo-
nents (COL1α2 and MMP2) in the supernatants was determined 
using commercial ELISA kits: human TNFα (Thermo Fisher, 
KHC3014), COL1α2 and MMP2 (Cloud Clone Corp., SEA215Hu 
and SEA100Hu). 
Statistical analysis 
Data were analysed using GraphPad Prism 7 (GraphPad Software, inc.) 
and expressed as mean values ± SD or mean values ± S.E.M. The Student t 
test was used for comparison between two groups. Data from three or 
more groups were analysed by one-way analysis of variance with Tukey’s 
multiple comparisons test. IHC analysis was performed in 5 independent 
areas/stain- ing, significance was calculated using Student t test. P < 0.05 
was considered to be significant. 
 
Table 1. TaqMan probes used for the research. 
 
Gene of interest Abbreviation Invitrogen Ref.nr. 
Actin Beta (Housekeeping gene) ACTB Hs99999903_m1 
Collagen 1 alpha 1 COL1α1 Hs00164004_m1 
Collagen 4 alpha 1 COL4α1 Hs00266237_m1 
Fibronectin 1 FN1 Hs00415006_m1 
CD44 (hyaluronic acid receptor) CD44 Hs01075861_m1 
Interleukin 6 IL6 Hs00985639_m1 
Transcription growth factor Beta 1 TGF-β1 Hs00998133_m1 
Actin, alpha 2, smooth muscle ACTA2 (αSMA) Hs00909449_m1 
Nuclear factor (erythroid-derived 2)-like 2 NFE2L2 (Nrf2) Hs00975961_g1 
Kelch-like ECH-associated protein Keap1 Hs00202227_m1 
https://doi.org/10.1371/journal.pone.0179995.t00
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Characterization of hTERT-HSC 
The hTERT-HSC cell lines showed typical stellate cell morphology with 
dendritic structure. The cells were highly proliferative and showed low ex-
pression of αSMA, a marker for activated stellate cells. Upon treatment with 
TGF-β1 or TNF-α, activation of hTERT-HSC cells was observed, indicated 
by enhanced staining for αSMA (Fig 1). TGF-β1 elicited stellate cell activa- 
tion after 2 days (with an increase of αSMA-positive cells from 10% to 90%), 
whereas 10-day stimulation was required with TNF-α to elicit a similar phe-
notype (Fig 1). 
Characterization of macrophages 
After differentiation of THP-1 monocytes to macrophages with PMA for 
48 h about 90% of THP-1 cells attached and spread showing the ex-
pected phenotype. Differentiated macrophages exposed to LPS (1 μg/mL) 
for 48 h showed the expected increase of TNF-α secretion. The level of 
secreted TNF-α was increased 5-fold by LPS in all the tested samples (Fig 
2). 10ng/mL PMA was chosen as minimal concentration for a stable differ-
entiation, since the cells easily detached after PBS washing in the 5 
ng/mL PMA samples. 
Morphological characterization of microtissues 
Microtissues (MTs) showed a regular spherical shape and a diameter of 
approximately 200– 350 μm. The presence of the three cell types in the 
co-cultures was demonstrated by the expres- sion of vimentin, marker of 
mesenchymal non-parenchymal cells, and CD68, marker for mac- 
rophages (Fig 3). In addition, we observed dendritic-shaped cells express-
ing vimentin, likely to be quiescent hTERT-HSC. The vimentin-positive 
cells are always located in the inner part of the microtissues, indicating a 
preferential spatial organization of the three cell types, with hTERT-HSC 
and macrophages located in the centre and surrounded by the hepato-
cytes. 
Fig 1. TNF-α and TGF-β1 promote αSMA production in monolayer culture of hTERT-HSC. hTERT-HSC cells were treated for 2, 5 or 10 
days with TNF-α (50ng/mL) or TGF-β1 (1ng/mL). After treatment, the cells were fixed and stained against αSMA (green) and nuclei (DAPI, 
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Fig 2. LPS induces TNF-α production in PMA-treated THP-1 cells. THP-1 were treated with 0, 5, 10 and 25 ng/mL PMA for 
48h prior exposure to 1 μg/mL LPS. The concentration of TNF-α was measured from the 48h culture supernatants by 
ELISA. These findings indicate that PMA differentiated THP-1 cells are well differentiated and yet respond adequately to a 




Responses to LPS, TNF-α and TGF-β1 
The treatment with LPS and TNF-α resulted in increased cellular viability 
of co-cultured microtissues, whereas TGF-β1 decreased their viability after 
14 days of treatment (Fig 4A). Sig- nificant decrease in cell viability was 
also showed after treatment with LPS and TNF-α in HepaRG-only mi-
crotissues, in contrast with the cell proliferation showed in the co-culture 
model with the same compounds. 
HepaRG showed a strong induction of IL-6 expression after stimula-
tion with LPS and TNF-α (Fig 5F). On the other hand and as expected, 
HepaRG monocultures, exhibited only moderate or no increase in ex-
pression of extracellular matrix proteins after stimulation with TGF-β1 
(Fig 5). 
In the co-cultures containing the three cell types, analysis of gene ex-
pression changes after treatment with LPS, TNF-α, and TGF-β1 showed 
a strong transcriptional induction of the extracellular matrix proteins colla-
gen I and IV, fibronectin, CD44, as well as the cytokines IL-6 and TGF-β1 
(Fig 5). 
 
Responses of multicellular MTs to the pro-fibrotic substances 
MTX and TAA 
In order to test whether the newly established in vitro model is ca-
pable of recapitulating induction of liver fibrosis, we tested the pro-
fibrotic chemicals methotrexate (MTX) and 
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Fig 3. Staining of formalin fixed paraffin embedded human microtissues generated with HepaRG-cells or Hep-
aRGs/THP-1/ hTERT-HSC. Microtissues were stained with Hematoxylin & Eosin (H&E), mesenchymal NPC-marker 
vimentin and macrophages marker CD68. Microtissues were kept in culture during 14 days before performing histological 
staining. Co-culture systems showed positive staining for vimentin and CD68 indicating the presence of the three different 
cell types. Arrows indicate CD68-positive cells. Dendritic stellate cells are shown in the zoom of vimentin staining picture. 




thioacetamide (TAA). Non-treated MTs were rather quiescent and main-
tained a relatively constant cell composition with minimal proliferation 
over at least 2 weeks (Fig 6). Exposure of co-culture MTs to MTX and 
TAA over 14 days showed a dose-dependent decrease in viability (Fig 
4B), mainly due to an effect on HepaRG cells. This is consistent with the 
decrease in albu- min staining detected by IHC (Fig 6). After TGF-β1 
stimulation, NPCs proliferated, as indi- cated by an increase of Ki67 and 
vimentin positive cells; the number of vimentin positive cells showed a 4-
fold increase as assessed by QISV (Fig 7). The increase in the CD68-, 
αSMA- and vimentin-positive cells, clearly show that a change in the cel-
lular composition of the microtis- sues is occurring after treatment with 
TGF-β1, MTX and TAA; in particular hTERT-HSC and THP-1 macro-
phages are proliferating at the expense of the HepaRG, which are de-
creasing. In addition, the increase in αSMA-positive cells demonstrated 
the activation of HSC. Thus, the MTs show a strong change in the cellu-
lar composition after stimulation with TGF-β1 and, to a lesser extent, with 
the profibrotic compunds MTX and TAA (Fig 7). The cellular defence 
mechanism was also activated upon treatment of the MT with TAA and 
MTX, as the mRNA levels of both Nrf2 and Keap1 were increased (Fig 
8). 
Extracellular matrix remodelling expected during the progression of 
fibrosis was observed in the MTs treated with the model compounds. 
Gene expression of MTs treated with MTX and TAA showed significant, 
dose-dependent transcriptional induction of collagen I, collagen IV, fi-
bronectin I and CD44 (Fig 8). The observed increase in gene expression 
resulted in increased secretion of collagen 1 and MMP2 in the superna-
tants at 14 days (Fig 9). These find- ings were further confirmed by the 
increased protein deposition of collagen I and αSMA observed by histo-
logical examination (Fig 7). 
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Fig 4. Viability response of human liver microtissues treated with pro-fibrotic compounds. (A) Effect of LPS, TNF-α and 
TGF-β1 on viability of human liver microtissues was assessed by MTT assay. Microtissues were incubated with 0.5mg/mL MTT 
solution for 4h after 14 days of exposure to the tested compounds. DMSO and Sö rensen buffer were then added into the wells and 
absorbance was read at 550nm using FlexStation 3. Values are expressed as percentage of negative control. *; P 0.05, **; P 
0.01, ***; P 0.001 vs vehicle control. (n = 6, mean ± SD). (B) Effect of MTX, TAA and TGF-β1 on the ATP production. ATP 
content was measured using CellTiter-Glo® Luminescent Cell Viability Assay 2.0 after 14 days of exposure to MTX, TAA 





In this work, we provide experimental evidence demonstrating that multi-
cellular MTs gener- ated with well characterized human cell lines can 
recapitulate the key cellular and molecular events leading to hepatic fi-
brosis. We reproducibly generated human liver MT using HepaRG, 
hTERT-HSC and THP-1, three human cell lines representing hepato-
cytes, macrophages and stellate cells. The use of stellate cells in culture 
has been attempted previously but often not considered a good option 
for the study of fibrosis in vitro due to the fact that stellate cells often un-
dergo spontaneous activation when grown on plastic dishes [24]. This is 
mainly due to the physical properties of cell culture dishes, which have a 
tissue tension greater than that of the fibrotic/cirrhotic liver (20 KPa) and 
much larger than that of normal liver tissue (5 KPa) [5]. hTERT-HSC 
have been reported to revert to a more quiescent status when cultured 
on extra- cellular matrix components [25]. In our hands, however, 
hTERT-HSC showed low levels of expression of the stellate cell activa-
tion marker αSMA before induction with TGF-β1. In both 2D culture and 
in the scaffold-free 3D MT, hTERT-HSC responded to pro-fibrotic stimuli 
such as LPS, TNF-α, TGF-β1 and pro-fibrotic compounds (MTX and 
TAA) by attaining an activated status. In the scaffold-free 3D liver MTs 
that we generated, the hTERT-HSC are kept in a more physiological en-
vironment, surrounded by other relevant cell types (HepaRG and THP1) 
as shown by IHC staining for αSMA and vimentin. In addition, the co-cul-
ture of 
HSC with hepatocytes and Kupffer cells is a model that incorporates all 
three cell types involved in the AOP leading to fibrosis, and is therefore very well 
suited to recapitulate cell- 
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Fig 5. Gene expression of fibrotic markers and cytokines in human liver microtissues exposed to 
LPS, TNF-α and TGF-β1. mRNA was extracted using TRIzol conventional procedure and fold induction were 
calculated as 2^(-ΔΔCT) for each sample and vehicle control and expressed as mean fold induction ± S.E.M of 
three replicates with six MTs each. Actin was used as reference gene for each sample. † pool of 16 microtis-
sues analysed as duplicate; no statistical analysis were performed on these samples. ND: no-detected val-







Fig 6. Albumin production and cell proliferation in liver microtissues. Formalin fixed paraffin embedded 
slides of HepaRG/THP-1 macrophages/hTERT-HSC microtissues were stained with Albumin and Ki67 anti-
bodies after 14 days of treatment with MTX, TAA and TGF-β1. Microtissues were fixed in 4% PFA and em-
bedded in 2% agarose prior paraffinization. Microtissues showed decrease in albumin production after MTX, 
TAA and especially TGF-β1 exposure. Ki67 shows strong induction of cell proliferation in the microtissues after 
TGF-β1 exposure. Scale bar: 200μm. Graphics show Quantitative IHC Staining Value (QISV) as mean ± S.D. 
(N = 5). *; P  ≤  0.05, 
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Fig 7. Immunostaining of formalin fixed paraffin embedded human microtissues after exposure to MTX, TAA and 
TGF-β1. Formalin fixed paraffin embedded slides of HepaRG/THP-1 macrophages/hTERT-HSC microtissues were stained with 
Hematoxylin & Eosin (H&E), vimentin, α-smooth muscle actin (αSMA), collagen I and CD68 after 14 days of treatment with 
MTX, TAA and TGF-β1. Microtissues were fixed in 4% PFA and embedded in 2% agarose prior paraffinization. Microtissues 
showed increase in the vimentin, αSMA, collagen I and CD68 positive cells after MTX, TAA and TGF-β1 exposure. Vimentin 
and CD68 stainings show proliferation of stellate cells and THP-1 macrophages in the microtissues, suggesting the onset of 
inflammation process, while αSMA and collagen I indicate activation of stellate cells and deposition of collagen. Scale bar: 
200μm. Graphics show Quantitative IHC Staining Value (QISV) as mean ± S.D. (N = 5). *; P  ≤  0.05, **; P  ≤  0.01, ***; P  ≤  0.001 




cell interactions leading to fibrosis in vitro. The results we obtained 
after stimulation with TGF-β1 clearly demonstrate that the hTERT-
HSC cell line is able to respond to well estab- 
lished pro-fibrotic stimuli by increasing the expression of the key factors: 
the activation marker αSMA and ECM proteins (collagen I and IV, fibron-
ectin, and CD44). Similarly, in our hands differentiated THP-1 macro-
phages served as an excellent surrogate for KC, as they were able to 
produce cytokines (in particular TNF-α) upon stimulation with LPS in both 
2D and 3D cul- tures. In our system, we used HepaRG cells as equivalent 
of hepatocytes. These cells are known to display many characteristics of 
human hepatocytes [26] including retention of metabolic activity [27]. 
Similarly to reported data with primary murine hepatocytes [28], HepaRG 
MTs responded to LPS and TNF-α by increasing transcription of IL6, 
showing for the first time that also HepaRG cells are able to produce IL6 
following injuring stimuli. HepaRG were also able to produce albumin in 
the 3D culture, indicating a functional phenotype up to three weeks in 
culture. However, albumin was significantly decreased after treatments 
with MTX and TGF- 
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Fig 8. Effect of MTX and TAA on gene expression of fibrotic markers in human liver microtissues. mRNA was extracted 
using TRIzol conventional procedure and fold induction were calculated as 2^(-ΔΔCT) for each sample and negative control and 
expressed as mean fold induction ± S.E.M. of three replicates with six MTs each. Actin was used as reference gene for each sam-
ple. *; P  ≤  0.05, 




β1 suggesting hepatocytes damage and onset of fibrosis in the microtis-
sues. The higher biologi- cal relevance of this model system allows study-
ing responses in an integrated biological system with intricate crosstalks 
between the main contributing cell types to fibrosis. For example, bio- logi-
cal response to LPS stimulation is only possible in presence of inflamma-
tion responsive cells (THP-1) and resulted in high activation of HSCs. 
This would not be possible in conven- tional monocultures. IHC staining 
for vimentin (as marker for NPCs) shows a physiological liver cell ratio of 
Hep/NPCs with approximately 80% hepatocytes, 20% NPCs including in-
flam- matory cells and stellate cells prior treatments. Thus, we were able to 
generate a complex cellu- lar model system with cell types and ratios 
which mimic in vivo liver organization. Moreover, with such model sys-
tems, it is for the first time possible to study in detail the contribution of 
the different cell types on induction and progression of fibrosis in an in 
vitro model system. 
 
Human liver MT recapitulate the sequence of events leading to fibro-
sis 
The recently published sequence of key events leading to liver fibrosis 
involve hepatocellular injury/death, KC-activation and macrophage re-
cruitment, TGF-β1 expression and release of cytokines (TNF-α and IL6), 
HSC activation, and collagen accumulation [29]. In Fig 10, we depicted 
our results in the context of the published AOP and of literature on 
known pathways related to liver fibrosis. Our results strongly indicate that 
the events leading to fibrosis in vivo can be reproduced by the herein 
described liver MT model system. 
39 
Hepatic fibrosis in an in vitro 3D-multicellular model 






Fig 9. Secretion of Collagen I and MMP2 in supernatant medium after exposure of microtissues to pro-fibrotic com-
pounds. 
Protein amount was assessed by ELISA in supernatant medium after 14 days of exposure to MTX, TAA and TGF-β1. *; P  ≤  




First: Hepatocellular injury/cell death was detected after exposure of 
MTs to TGF-β1, MTX and TAA by cell viability assays where the treat-
ments caused a dose-dependent decrease in via- bility. Hepatocyte dam-
age was also highlighted by albumin staining with a complete loss of al-
bumin after exposure to TGF-β1. With LPS, TNF-α, TGF-β1 we could 
demonstrate that the major target of the cytotoxicity in the co-culture sys-
tem were the HepaRG cells. MTs consist- ing of HepaRG alone showed 
a decrease in cell viability, while in co-culture systems there seemed to 
be an increase in the number of living cells. This suggests compensation 
due to the proliferation of hTERT-HSC and/or THP-1 macrophages. Im-
munostaining results (Ki67 and vimentin), confirm the proliferation of vi-
mentin-positive non-parenchymal cells and macro- phages (expressing 
CD68) after TGF-β1 stimulation. HepaRG injury could also be confirmed 
by upregulation of mRNA level of IL6 after exposure to LPS and TNF-α, 
suggesting the onset of an inflammatory response. 
Second: Hepatic KC and macrophages are usually responsive to the 
TLR4-ligand LPS by increased cytokine release [30]. After exposure of 
liver microtissues to LPS, we detected an increase of expression of 
TNF-α, IL6 and TGF-β1, indicating the onset of an inflammatory re-
sponse. Moreover, treatment of microtissues with TNF-α, also led to 
increased expression and secretion of TGF-β1, produced either by the 
THP-1 cells or by the hTERT-HSC in agree- ment with a described auto-
crine loop [31]. 
Third: The last cellular events in the cascade leading to liver fibrosis in-
volve activation of stellate cells and ECM-remodelling [29]. This was also 
observed in our system as exposure of MTs to TGF-β1 led to an increase in 
the number of αSMA-positive cells and the induction of 
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Fig 10. Molecular signalling between hepatic stellate cells, Kupffer cells and hepatocytes after liver injuries. The picture 
shows the potential complex interactions between matrix-producing hepatic stellate cells and liver-resident macrophages and 
hepatocytes after liver injuries such as pro-fibrotic compounds (MTX and TAA). Some of these interactions have been previ-
ously published, some are supported by our data and some are still speculative. In our liver microtissues THP1 macro-
phages (as surrogate of Kupffer cells) produced large amount of TNF-α, IL6 and TGF-β1 detected by increase in gene 
expression. HepaRG (hepatocyte-like cells) also produced cytokines (IL-6) after specific stimulation such as LPS and TNF-α 
and showed hepatocyte damage after exposure to TGF-β1 as demonstrated by decreased albumin staining. The cytokines 
were able to enhance stellate cell activation (increase in αSMA production) and collagen deposition. Furthermore increase 
in expression of oxidative related genes, such as Nrf2 and Keap1, was measured at high concentrations of MTX and TAA 
suggesting the involvement of this cellular defence. Arrows indicate measured parameters. 
https://doi.org/10.1371/journal.pone.0179995.g010 
 
ECM components (collagen I, IV, fibronectin, CD44, and MMP2). CD44 
(hyaluronic acid receptor) is usually upregulated in stellate cells of injured 
liver and it is also correlated to their activated and migratory phenotype 
[32]. Also MMP2 upregulation in the supernatant con- firms the remodel-
ling of the ECM, as previously published [33]. Thus, the co-cultured MTs 
were able to recapitulate the described cellular key events that lead to 
liver fibrosis. 
 
Response of liver microtissues to pharmacologically induced fibrosis 
Similar to the results obtained with the positive control TGF-β1, both MTX 
and TAA induced strong expression of ECM-components and a rear-
rangement of the cellular composition of the MTs: increased numbers of 
vimentin-positive NPC cells appeared surrounded by big and round 
apoptotic cells that could be the injured HepaRG, as also supported by 
the decrease in albumin. These NPCs contributed to changes in the 
ECM, demonstrated by the increased secretion and deposition of colla-
gen I, the strong transcriptional induction of hyaluronic acid receptor 
(CD44) and fibronectin, as well as a 10-fold increase in secretion of 
MMP2 into the medium. Taken together, the results suggest an increase 
in the propensity of the stellate cells to become invasive and highly prolif-
erative and demonstrate the remodelling of the ECM upon challenge of 
liver MT with fibrotic compounds. All these effects were more pro-
nounced in TAA-treated samples than in MTX-treated samples. 
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In addition to the effects on viability and ECM, the involvement of oxi-
dative stress and the activation of the Nrf2 pathway in liver fibrosis have 
previously been reported [10]. The induc- tion of Nrf2 and Keap-1 after 
exposure to MTX and TAA clearly indicates that this cellular defence 
mechanism is active in our culture system. In the early stages of fibrosis, 
ROS pro- duced directly by injured hepatocytes and/or recruited neutro-
phils could directly induce acti- vation of Kupffer cells and macrophages 
[34]. The Nrf2 and Keap-1 gene upregulation we measured in our system 
could be related to similar protective mechanisms, but due to the mul- ti-
cellular nature of the co-cultured MT, we cannot pinpoint if this pathway 
has been activated in the HepaRG cells or in the THP-1 or hTERT-HSC. 
 
Conclusion 
Summarizing, in this study, we have demonstrated that a 3D-liver MT co-
culture containing HepaRG, THP-1 and hTERT-HSC is able to recapitu-
late the known cellular events leading to the fibrotic phenotype [29]. 
Treatment with pro-fibrotic substances demonstrates that this system 
reproduces the key cellular and molecular events including hepatocellular 
injury, activation of the cellular defence pathway, macrophage activation, 
stellate cell activation and deposition of ECM (Fig 10). Phar- macological 
interventions (pro-fibrotic compounds, LPS, TNF-α and TGF-β1) at several 
levels of the fibrosis AOP [29] provided convincing evidence supporting 
that the described sequence of cellular events could be reproduced in 
vitro. 
The application of such a system would be a great contribution for the 
further understand- 
ing of the mechanism through which clinically relevant compounds lead 
to liver fibrosis. The implementation of this system for the detection of 
potential pro-fibrotic compounds may replace currently used animal 
studies. In addition, the model system allows testing of anti- fibrotic com-
pounds in a physiological relevant in vitro system, providing researchers a 
novel tool to study inhibition of fibrosis progression. 
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The research goal addressed in Project 1 was to develop new liver models able to recapitulate 
all the key events leading to fibrosis. In the first paper (Prestigiacomo V et al., Journal of Toxico-
logical and Pharmacological Methods 2019), the isolation of KC and HSC from a single liver ho-
mogenate was optimized to a single step process allowing a quick and inexpensive purification 
of the required cells. However, the main achievement of this paper was the establishment of a 
primary cell culture system with rat hepatocytes, KC and HSC to investigate liver fibrosis using 
the hanging drop technology in a 96-well format. In these 3D MTs the key phenotypical charac-
teristics of functional cells were maintained, such as albumin production for the hepatocytes, re-
lease of TNF-α from KC and production of desmin and αSMA for HSCs. In addition, this model 
responded to LPS and TGF-β1, which induced αSMA expression, affected cell viability and in-
duced release of cytokines. In addition, it is noteworthy that pre-activated HSC partly reverted to 
the inactive phenotype when cultured in 3D MTs, as shown by the loss of αSMA production. This 
last evidence suggests that HSC may have a transmutable phenotype that comes to play in the 
established 3D-co-culture system. The investigation of the molecular mechanism behind this plas-
ticity could be of great significance in investigating potential pharmacological interventions to treat 
liver fibrosis. This model represents the first system with both rat primary parenchymal, KC and 
HSC generated with a simple and reproducible method with the ability to recapitulate fibrotic 
events in vitro.  
In the second paper of this chapter (Prestigiacomo V et al., PLoS ONE 2017), a human 3D-liver 
co-culture model containing HepaRG, THP-1 macrophages and hTERT-HSC was successfully 
established and characterized. This model responded to pro-inflammatory stimuli (LPS, TNF-α 
and TGF-β1) as well as to pro-fibrotic stimuli (MTX and TAA), resulting in a fibrotic phenotype in 
vitro. HepaRG showed hepatocyte damage after exposure to MTX, TAA and TGF-β1 as demon-
strated by decreased albumin staining. In this model THP-1 macrophages (as surrogate of Kupffer 
cells) produced large amount of TNF-α, interleukin 6 and TGF-β1 detected by increase in gene 
expression. In addition, the tested compounds were able to enhance HSC activation (increase in 
αSMA production) and collagen deposition. Furthermore increase in expression of oxidative re-
lated genes, such as Nrf2 and Keap1, was measured at high concentrations of MTX and TAA 
suggesting the involvement of this cellular defence pathway. This system showed all the key 
events of fibrosis, such as hepatocyte damage, oxidative stress, HSC activation, ECM remodel-
ling and chronic inflammation. Remarkably, all these events were elicited after exposure to liver 
cytokines or toxicants administration. This system can thus be used for the investigation of cellular 
and molecular events involved in the development of fibrosis as well as an in vitro test system for 






 Project 2: PDGF, TGF-β1 and Nrf2 in the regulation of hepatic 
stellate cell activation 
4.1 Introduction  
As described in chapter 2.2, the initiation and perpetuation of HSC activation require specific 
signalling pathways. In particular, the mitogenic growth factor PDGF, as well as the fibrogenic 
TGF-β1, plays a crucial role during HSC activation. PDGF has been identified as the most potent 
mitogen for HSCs for more than 20 years [100]. PDGFs are members of the cysteine-knot-type 
growth factors, and consist of five known dimer configurations (AA, AB, BB, CC, DD), formed by 
four different disulfide-bonded polypeptide chains (A, B, C, D) [101]. All the different chains share 
a common growth factor domain of around 100 amino acid residues in length, and the accessory 
amino acid sequences found in the N- or C-terminal extensions of all PDGF chains are involved 
in the regulation of the biological properties of these factors [102]. PDGFs are synthesized and 
assembled into disulphide-linked dimers in the endoplasmic reticulum as inactive precursors and 
proteolytic processing is necessary for activation and biological function. PDGF-AA, PDGF-AB 
and PDGF-BB are cleaved and activated in the exocytic pathway, whereas PDGF-CC and PDGF-
DD are cleaved and activated extracellularly [103–105]. PDGF dimers transduce their signals by 
binding to α- and β- class III tyrosine kinase receptors (PDGFRα and PDGFRβ), which consist of 
five extracellular immunoglobulin-like domains and an intracellular tyrosine kinase domain [106]. 
The five dimeric isoforms of PDGF display distinct abilities to bind and activate the two PDGFRs. 
PDGF-AA, PDGFAB, PDGF-BB and PDGF-CC can bind to and activate PDGFRα, while PDGF-
BB and PDGF-DD can specifically bind to and activate PDGFRβ. PDGF-AB, PDGF-BB and 
PDGF-CC can also stimulate heterodimeric PDGFRα/β complexes [102]. Following PDGF bind-
ing, receptor dimerization occurs. This process brings the intracellular domains of the receptor 
close to each other, promoting autophosphorylation in trans, leading to the activation of the kinase 
domain and to the several downstream cascades, such as phosphatidylinositol 3-kinase, phos-
pholipase C-γ, the Src family of tyrosine kinases, the tyrosine phosphatase SHP-2, and mitogen-
activated protein kinase (MAPK) [106]. The activation of these signalling pathways leads to stim-
ulation of cell growth, but also to changes in cell shape and motility. Although platelets are a major 
storage site, PDGFs are widely expressed in many cell types. In particular, HSCs express only 
the A- chain of PDGF, while both receptor isoforms are present on their membrane [23,100]. 
During fibrosis an increase of PDGFRβ has been shown during early phase of HSC activation 
[107], and depletion of PDGFRβ in HSCs led to the decrease of injury and fibrosis [108]. 
TGF-β1 has been identified as the most potent fibrogenic cytokine in the liver, since it directly 
induces HSC activation [23]. TGF-β1 is a secreted polypeptide member of the transforming 
growth factor beta superfamily of cytokines, and it performs many cellular functions, including the 




β2, and TGF-β3) of the five existing isoforms of TGF-β are expressed in mammals. These factors 
are synthesized as inactive precursors, which do not bind to their receptors and have no biological 
effect [110]. Prior secretion, the factor is cleaved in the N-terminal pro-region, known as latency-
associated peptide (LAP); despite the cleavage, the LAP domain remains associated with the rest 
of the protein, facilitating the transit of TGF-β out from the cell [110]. This latent complex may 
associate with latent-TGF-β-binding protein, necessary for the TGF-β targeting to the extracellular 
matrix [110]. Serine protease, plasmin, neuraminidase, cathepsins B and D, and thrombospondin-
1, as well as other proteases and changes in the pH can convert LAP-TFG-β to biologically active 
TGF-β [110]. Once activated, the TGF-β homodimers transduce their signal by bringing hetero-
tetrameric complexes of type II (TβRII) and type I (TβRII or ALK5) serine/threonine kinase recep-
tors. The constitutively active TβRII then leads to phosphorylation-dependent activation of TβRI 
[109]. To transduce its signal, the activated TβRI recruits many molecular mediators, which is 
possible to categorize in Smad and Non-Smad pathways [111]. Among the Non-Smad pathways, 
the MAPK family, Rho-like GTPases and phosphatidylinositol 3-kinase/Akt play a crucial role in 
the TGF-β mediated signal transduction [111]. Components of the MAPK pathway, as Ras, 
ERK1/2, p38, and JNK play a key role in the cellular response to pro-inflammatory cytokines, 
environmental stress signalling and apoptotic agents after TGF-β stimulation [112]. It has been 
shown that p38 MAPK activity influences cell activation in quiescent hepatic and pancreatic stel-
late cells [113,114]. TGF-β-induced activation of Rho-like GTPases induces the exchange of GDP 
for GTP, leading to the stimulation of ROCK kinases, which in turn phosphorylate numerous sub-
strates including the LIM kinases [115]. ROCK activation increases actin–myosin contractile force 
generation, with a contribution from LIMK-induced actin filament stabilisation in epithelial cells, as 
well as differentiation of lung fibroblast into αSMA-expressing myofibroblasts [115,116]. However, 
despite the relevant role of Non-Smad pathways in the TGF-β cascade, the canonical Smad path-
way remains the main molecular mechanism for TGF-β-induced signals. The activated TβRI in-
duces the phosphorylation of the cytoplasmic signalling molecules receptor-regulated Smads (R-
Smads); in particular the phosphorylation of Smad2 and Smad3 induces their partnering with the 
signalling transducer Smad4, and their translocation to the nucleus [117]. In the nucleus the R-
Smad complex interact interacting with transcriptional co-activators like p300 and Creb-binding-
protein, or repressors like SkiL or TGIF, to regulate the expression of target genes [118]. It has 
been shown that Smad3 is required for HSC matrix production and matrix interaction, by promot-
ing collagen and fibronectin expression [119]. Furthermore, TGF-β1 signalling is required for 
αSMA production and its organization in stress fibres [120]. A TGF-β1 control element (TCE) as 
well as two potential Smad3-binding elements have been identified in the αSMA promoter of rat 
lung smooth muscle cells and fibroblasts, respectively [121,122]. Beside the R-Smad, also inhib-
itory Smads are involved in the pathway regulation. Particularly, Smad7 is a general antagonist 




phosphorylation [109]. Furthermore, Smad7 can recruit the E3 ubiquitin ligases, such as Smurf1 
and Smurf2, which are involved in the degradation of ALK5 receptor via proteasomal pathway 
[109]. 
Oxidative stress has been recently identified as a modulator of HSC activation and fibrosis [46,47]. 
It was reported that oxidative stress may directly affect PDGF and TGF-β1 pathways [123,124]. 
Lipid peroxidation products (e.g. 4-hydroxy-2-nonenal) have been shown to induce the expression 
of PDGF in rat aortic smooth muscle cells with consequent stimulation of cell growth [124], while 
TGF-β1 has been shown to modulate and be modulated by oxidative stress in many different 
ways. TGF-β1, in fact, does not only induce ROS production in mitochondria and microsomes in 
hepatocytes, but also downregulates the expression of antioxidant enzymes such as glutaredoxin, 
catalase, superoxide dismutase, and glutathione peroxidase during fibrogenic diseases [125–
127]. TGF-β1 also increases the expression of the transcription factor ATF3 which decreases the 
cellular amount of GSH by inhibiting the expression of the GSH catalytic subunit gamma-glutamyl-
cysteine synthetase [128,129]. On the other hand, ROS directly modulate the TGF-β1 by acting 
on the LAP fragment of the latent complex [123]. ROS can also modulate the activity of phospha-
tases (such as PTP1B, PP2A, MKP-1 and PPM1A) that can indirectly modulate the TGF-β path-
way by acting on the activation state of Smad protein and MAPKs [123,130,131]. Oxidative stress, 
mediated partly by lipid peroxidation products, induces collagen synthesis in rat HSCs [132]. As 
the other liver cells, quiescent HSCs present protective mechanisms against oxidative stress such 
as enzymes from the GST family, which form GSH conjugates with lipid peroxidation products 
(e.g. 4-hydroxy-2-nonenal) [132]. Upon activation, HSCs lose most forms of GST and associated 
enzymatic activities, becoming then more susceptible to oxidative stress [132]. Nrf2 was found to 
be active in HSCs, and in particular it was shown that rat activated HSCs express significantly 
lower level of Nrf2 compared to quiescent cells [47]. Consistently, Keap1 increases significantly 
in activated HSC, suggesting a possible regulative mechanism of Nrf2 pathway in HSC activation. 
In the same study, TGF-β1 was reported to reduce the presence of Nrf2 in a rat HSC cell line, by 
acting through the epigenetic regulation operated by the microRNA-200a [47]. Nrf2 also inhibits 
TGF-β1-induced expression of fibrosis markers in a human HSC cell line [47]. In human renal 
tubular epithelial cells, Nrf2 reduces the transition to fibroblast as well as collagen and fibronectin 
production [83]. Smad7 has been identified as the molecular effector of this pathway; in Keap1 
knockdown cells, Smad7 was indeed elevated, promoting a strong inhibition of the TGF-β1 path-
way. In HepG2 cells, Nrf2 suppresses phosphorylation, nuclear translocation, and DNA binding 
of Smad3 [81]. A deeper characterization of Nrf2 pathway in human HSCs may reveal a suitable 
pathway to which act in order to protect from or revert HSCs activation.  
This chapter is divided into two main parts based on the different pathways studied in relation to 
HSC activation. Both studies were carried out on primary HSCs as well as hTERT-HSCs, focusing 




two key cytokines involved in HSC activation, PDGF and TGF-β1, focusing on the understanding 
of how they interact with each other in regulating HSC activation in vitro. Indeed, despite their 
well-known involvement in HSC activation, the specific role of those two key factors remains un-
clear, mostly due to the lack of recent studies on human primary HSC. The second study focuses 
on the role of Nrf2 pathway in HSC and on its potential intervention during activation and fibro-
genesis in relation to TGF-β1/Smad pathway. Although the Nrf2 role in hepatocytes and liver 





4.2 Paper 3 
 
TGF-β1 and PDGF control different aspects of stellate cell activation 
during liver fibrosis 
 









Aims: Elucidate the role of TGF-β1 and PDGF on the main cellular process that characterize 
HSC activation, such as proliferation, migration and differentiation.  
Results: TGF-β1 treatments elicited HSC activation, characterised by production of αSMA and 
collagens, while PDGF-AB treatment induced proliferation and cell migration in both primary and 
hTERT-HSCs.  
Conclusion: These data suggest that both independent pathways represent key events leading 
to HSC activation in vitro. However, to achieve full cell activation, simultaneous exposure of HSCs 
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Liver fibrosis is a reversible wound-healing response to acute or chronic cellular injury. The pri-
mary effector cell of liver fibrosis is the hepatic stellate cell (HSC), which orchestrates the depo-
sition of extracellular matrix in normal and fibrotic liver. The aim of this work was to elucidate 
cellular processes involved in HSC trans-differentiation, such as proliferation, migration and dif-
ferentiation, to better understand the role of key signalling pathways in the development of fibro-
sis. 
Following stimulation of human primary and immortalised (hTERT) HSCs with TGF-β1 and/or 
PDGF-AB we evaluated cell viability, activation state trough smooth muscle α-actin (αSMA) ex-
pression, proliferation, migration, as well as gene expression for of activation and fibrosis mark-
ers. 
Upon exposure to TGF-β1, HSCs transdifferentiated into myofibroblasts-like cells, which produce 
αSMA and collagens. Contrarily, PDGF-AB-treatment did not affect the cellular activation and 
fibrogenic capacities, but induced proliferation and cell migration in a concentration-dependent 
manner. Simultaneous exposure of HSCs to both factors showed a synergistic effect leading to 
full cell activation. These data suggest that both independent pathways converge and represent 
key events leading to HSC activation in vitro. Moreover, primary and hTERT-HSCs behave simi-
larly, identifying this HSC cell line as a suitable model to study HSC activation in vitro. 
 






Hepatic fibrosis is a complex fibrogenic and inflammatory process that results from perpetuation 
of the normal wound healing response, triggered by chronic liver injury (including chronic viral 
hepatitis infection, non-alcoholic fatty liver disease, alcoholic liver disease, cholestasis and auto-
immune liver disease) [1, 2] . Chronic hepatocyte death leads to the release of cellular contents 
(e.g. DNA and damage-associated molecular patterns known as DAMPs) that activate resident 
macrophages (Kupffer cells) that produce large amounts of reactive oxygen species and release 
pro-inflammatory cytokines such as TNFα, TGF-β1, PDGF and IL-1β, leading ultimately to stellate 
cell (HSC) activation [2, 3] . 
HSCs constitute 5-8% of all liver cells and are found in the sub-endothelial space of Disse, be-
tween the anti-luminal side of sinusoidal endothelial cells and the basolateral surface of hepato-
cytes [4, 5] . During the last decades, HSCs, were mainly viewed as “storing cell”, with the main 
role of storying approximately 80% of the body's vitamin A (retinol, retinoic acid), and synthesizing 
extracellular matrix (ECM) components in the normal and fibrotic liver [5, 6] . Nevertheless, it has 
been reported that HSCs can activate the immune response by releasing cytokines and directly 
acting as antigen presenting cells; they can also contribute to angiogenesis, hepatocyte regener-
ation and the regulation of oxidant stress [5–7] .  
After liver injury, HSCs undergo an activation process, losing their content of lipid droplets and 
transdifferentiating from quiescent vitamin A storing cells into smooth muscle α-actin (αSMA) pos-
itive myofibroblasts-like cells. Activated HSCs produce a network of fibrillar collagen and fibron-
ectin, replacing the low-density, basement membrane-like matrix of the liver [2, 8] . The activation 
process is temporally divided into an initiation phase, that renders the cells responsive to cyto-
kines and other local stimuli, and a perpetuation phase, where the cells maintain the activated 
phenotype and generate fibrosis [6] .  
HSC initiation and perpetuation requires specific signalling pathways; thus, understanding how 
they interact with each other can contribute to the identification of possible therapeutic interven-
tions to revert HSC activation and hepatic fibrosis. Of particular importance for the HSC are 
growth factor and fibrogenic signalling pathways. More that 20 years ago, platelet-derived growth 
factor (PDGF) was identified as the most potent mitogen for HSCs [9] . The PDGF family consists 
of disulphide-bonded homodimers of A-, B-, C- and D-polypeptide chains, and the heterodimer 
PDGF-AB [10] . PDGF dimers transduce their signals by binding to α- and β- class III tyrosine 
kinase receptors (PDGFRA and PDGFRB), which consist of five extracellular immunoglobulin-
like domains and an intracellular tyrosine kinase domain [10] . While the production of only the A- 
chain of PDGF has been shown in HSC, both receptors can be detected on their membrane; in 
particular an increase of PDGFRB has been shown during early phase of HSC activation [6, 9, 




changes in cell shape and motility in HSC [12, 13] . However, HSCs lead to fibrosis not only by 
increasing the cell number, but also increasing the ECM production per cell [6] . In particular, 
TGF-β1 has been identified as the most potent fibrotic cytokine in the liver [6, 14] . After liver 
injury, TGF-β1 is released from the activated Kupffer cells leading to HSC activation with the 
consequent release of ECM [15] . During the perpetuation phase, HSCs produce TGF-β1 main-
taining an positive autocrine loop [14, 16] . Hallmarks of TGF-β1-induced HSCs are αSMA pro-
duction, as well as the remodelling of ECM, with deposition of fibrillar collagens and fibronectin 
and release of metalloproteinases (MMPs) [2] . 
Although the involvement of several signalling pathways in the activation of HSC has been rec-
ognized, the specific role of some key factors remains unclear. Recently, Kikuchi et al. showed 
the effect of PDGFs on proliferation and migration of human HSCs, but no date are yet available 
about the effect of TGF-β1 on those cellular processes [17] . The aim of our work was to elucidate 
the dynamic range of human hepatic HSC transdifferentiation. Using human primary HSC and 
immortalised HSC (hTERT-HSC), we evaluated changes of several cellular processes, such as 
proliferation, migration and activation in presence of TGF-β1 and/or PDGF-AB. Here, we report 
that simultaneous exposure of hTERT-HSC to both factors showed a synergistic effect leading to 




Material and methods 
Reagent and chemicals  
DMEM High Glucose (41965; Invitrogen), Fetal Bovine Serum (10270; Invitrogen), Penicillin-
Streptomycin (A8943; Applichem), TGF-β1 (T5050; Sigma), PDGF-AB (P8147; Sigma), SB-
431542 hydrate (SB43) (S4317; Sigma), SB-525334 (SB52) (S8822; Sigma). Triton X-100 
(T8787; Sigma), Bovine serum albumin (05473; Fluka), formaldehyde (18814; Polysciences), 
αSMA antibody (A5228; Sigma), secondary antibody Alexa Fluor® 488 F(ab')2 Fragment of Goat 
Anti-Mouse IgG (H+L) (A11017; Invitrogen), DAPI (D9542; Sigma) and Propidium Iodide (7109; 
Sigma). 
Cell culture 
Human primary HSCs were purchased from iXCells Biotechnologies, USA, (Cat. 10HU-210) or 
Innoprot, Spain (Cat. P10653). They were cultured in DMEM High Glucose supplemented with 
10% Fetal Bovine Serum and 1% Penicillin-Streptomycin and used up to 5 passages.  hTERT-
HSC were kindly provided by Dr. Bernd Schnabl (UC San Diego, USA) [8]  and were cultured in 
DMEM High Glucose supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomy-
cin up to 12 passages. The cells were kept in the humidified incubator at 37˚C with 5% CO2. 
Cell viability assay  
A cell density of 3 x 104 cells/cm2 was seeded in a 96-well plate and incubated with chemicals at 
37oC, after overnight cell attachment. The cells were treated with 0-20 ng/mL TGF-β1 or 0-30 
ng/mL PDGF-AB in serum-free medium. The treatments were refreshed every day for all the du-
ration of the experiment. The assay was performed after 24 hours, 48 hours and 7 days of expo-
sure by incubation of the samples with 100 μL Cell Counting Kit-8 (96992; Sigma), diluted 1:10 
with DMEM medium for 2 hours. Following, the volume was transferred in a 96-well microplate 
and the absorbance was measured at 450 nm by using the FlexStationTM 3 Microplate Reader. 
Wells without cells were used as blank. CyQUANT® NF Kit (C35006; Thermo Fisher) was used 
to normalize the viability data with the number of cells. 
Immunocytochemistry analysis 
To assess the activation state of the cells, immunostaining for αSMA was performed for both 
TGF-β1- and/or PDGF-AB-treated and untreated cells. The two Smad inhibitors SB43 [18]  (10 
µM) and SB52 [19]  (1 µM) were used as well. The cells were fixed in 4% formaldehyde for 15 
minutes, followed by permeabilization with 0.1% Triton-X-100 for 20 minutes. Blocking was per-
formed with 1% bovine serum albumin in PBS for 60 minutes, followed by incubation with primary 
antibody against αSMA (dilution 1:200 in blocking solution) for 90 minutes. Incubation with sec-




temperature and washing steps with 1X PBS were conducted between each step and at the end. 
DAPI and Propidium Iodide were used to stain the nuclei.  
Click-iT EdU Proliferation assay 
The Click-iT® EdU Alexa Fluor® 488 Imaging Kit (C10637; Invitrogen) was used to measure the 
proliferation rate of the cells after treatments. 3 x 104 cells/cm2 were seeded in 96-well plate format 
and immediately treated with 0.5-1 ng/mL TGF-β1, 1-5 ng/mL PDGF-AB and a mixture with 1 
ng/mL TGF-β1 and 5 ng/mL PDGF-AB for 48 hours. EdU dye was added only during the last 30 
hours of each experiment and detected following manufacture’s instructions. The pictures were 
acquired with the Olympus Laser Confocal Scanning Microscope FV1000D spectral type (inverted 
microscope IX81) and analysed with ImageJ to determinate the proliferation rate.  
Gene expression analysis  
RNA from TGF-β1 and PDGF-AB-treated cells (with and without Smad inhibitors), was isolated 
following TRIzol extraction procedure. RNA was reverse transcribed using a reverse transcriptase 
(Promega) and oligo dT (Qiagen) and real time PCR was performed using FastStart TaqMan Mix 
(Roche) and TaqMan probes from Invitrogen. Real time, Taqman qPCR was performed on se-
lected genes (αSMA, catenin β1, collagen I, collagen IV, fibronectin 1, CD44, Lox, Loxl2, MMP2, 
PDGFRA, PDGFRB, Snail1) (see Table 1). The following qRT-PCR Program was used: 10 
minutes denaturation at 95˚C, followed by 40 cycles of 15 seconds at 95˚C and 1 minute at 60˚C. 
The Ct values were assessed using the Corbett Rotorgene Analysis Software 6000 and B2M was 



















The migratory capacity of HSCs was investigated using the Culture-Insert 2 Well (80209; Ibidi) 
according to the manufacturer's instructions. Briefly, 70 μL of 3 x 105 cells/mL suspension were 
incubated in each chamber in serum-free medium overnight. After cell attachment, the culture 
insert was gently removed by using sterile tweezers, leaving a cell-free gap of approximatively 
500 µm. Medium was slowly aspired and 1 mL/well of serum free DMEM medium was added. 
HSC migration was evaluated in presence of TGF-β1, PDGF-AB and SB52 inhibitor. The wound 
healing process was followed by time laps microscopy, using Olympus cellVivo incubation system 
with 4X magnification. Pictures were acquired every hour for a period of 48 hours. Pictures were 
analysed with ImageJ and migration area was calculated with MRI Wound Healing Tool 
(http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool) as previously published 
[20] . 
Statistical analysis 
Experiments with primary HSC were conducted with at least 3 batches of cells as indicated in the 
legend. Data were analysed using GraphPad Prism 7 (GraphPad Software, inc.) and expressed 
as mean values ± standard deviation (SD) as indicated in the legend. The Student’s t-test was 
used for comparison between two groups. Data from three or more groups were analysed by one-
way analysis of variance with Tukey's multiple comparisons test. P ≤ 0.05 was considered to be 
significant.   
Gene of interest Abbreviation Invitrogen Ref.nr. 
Beta-2-microglobulin (Housekeeping gene) B2M Hs00187842_m1 
Actin, alpha 2, smooth muscle ACTA2 (αSMA) Hs00426835_g1 
Catenin beta 1 CTNNB1 Hs00355049_m1 
Collagen 1 alpha 1 Col I Hs00164004_m1 
Collagen 4 alpha 1 Col IV Hs00266237_m1 
Fibronectin 1  FN1 Hs00415006_m1 
Hyaluronic acid receptor CD44 Hs01075861_m1 
Lysyl oxidase Lox Hs00942480_m1 
Lysyl oxidase like 2 Loxl2 Hs00158757_m1 
Metalloproteinase 2 MMP2 Hs01548727_m1 
PDGF receptor alpha PDGFRA Hs00998018_m1 
PDGF receptor beta PDGFRB Hs01019589_m1 





TGF-β1, but not PDGF-AB, induces αSMA production 
TGF-β1 and PDGF-AB did not show any cytotoxicity effect on hTERT-HSC over 7 and 6 days, 
respectively (Fig. 1 A-B). Viability assays values were normalized with the cell number by using 
the CyQuant assay, in order to eliminate the influence of cell proliferation on cell viability. Treated-
cells displayed up to 2-fold and almost 1.5-fold higher activity of cellular dehydrogenase than 
untreated-cells for TGF-β1 and PDGF-AB respectively, suggesting an increase of metabolic ac-
tivity. Based on these results, 0.5-1 ng/mL TGF-β1 and 1-5 ng/mL PDGF-AB were chosen for the 
subsequent experiments. Untreated hTERT-HSC and primary HSC showed low αSMA production 
(Fig. 1 C-D); TGF-β1 elicited HSC activation after 48 hours (with an increase of αSMA-positive 
cells from approximately 10% to 90%) in both immortalised and primary HSC. This induction was 
strictly correlated to TGF-β1/Smad pathway as it was inhibited by simultaneous incubation with 
the Smad inhibitors SB43 and SB52. Incubation of hTERT-HSC with PDGF-AB did not increase 
αSMA production. 
Proliferation and migration of HSCs require PDGF-AB signalling  
To explore the proliferative and migratory capacities of HSC, we performed an EdU proliferation 
assay and a wound healing assay after exposure to TGF-β1 and/or PDGF-AB. The proliferation 
rate was 70% for hTERT-HSC, and dependent on batch the primary HSC proliferated within a 
range of 30-70%. PDGF-AB induced cell proliferation already at the concentration of 1 ng/mL, 
with a concentration-dependent effect on primary HSC (Fig. 2 A-B). PDGF-AB also played a dom-
inant role in leading the complete repair of the wound gap even when combined with TGF-β1. 
hTERT-HSC treated with 5 ng/mL PDGF-AB for 24 hours displayed 3.5-fold higher migration rate 
than the untreated controls; while primary HSC treated for 12 hours migrated 4 times faster than 
their untreated counterparts (Fig. 3 A-B).  In particular, the proliferation rate raised from 70% to 
87% for hTERT-HSC and from 50% to 67% for primary HSC after exposure to 5 ng/mL PDGF-
AB. In contrast, TGF-β1 and SB inhibitors did not have any significant effects on migration of 
neither immortalized nor primary HSCs (Fig. 3 A-B). Moreover, TGF-β1 did not change the prolif-
eration rate of primary HSC and led to a dose-dependent decrease in proliferation of hTERT-
HSCs (Fig. 2 A-B). Immunohistochemical analysis during the wound-healing process (Fig. 4) 
clearly demonstrates the complementary effects of TGF-β1 and PDGF-AB. hTERT-HSC treated 
with TGF-β1 do not migrate but display a clear activated phenotype as demonstrated by the 
presences of αSMA stress fibres (Fig. 4 B). PDGF-AB, on the other hand, leads to widespread 
migration and no increase in αSMA-positive cells (Fig. 4 C). The combination of both factors elicit 





TGF-β1 is essential for HSCs activation 
To assess the pro-fibrogenic effect of both TGF-β1 and PDGF-AB, mRNA levels of several HSC 
activation markers as well as ECM components were analysed in both immortalized (Fig. 5) and 
primary (Fig. 6) HSC. TGF-β1 at 1 ng/mL, but not PDGF-AB, elicited a significant increase in gene 
expression of αSMA, Collagens I and IV (Col I and Col IV) as well as fibronectin (FN1), hyaluronic 
acid receptor (CD44) and Lox genes (Figs. 5 and 6), suggesting an effect on the ECM remodel-
ling. Significant increases were also observed for αSMA, Snail1, CD44 and Lox, indicating acti-
vation of HSC by TGF-β1. Additional treatment with SB43 and SB52 blocked the effect of TGF-
β1 for all measured genes, especially on the hTERT-HSC. In these cells, the inhibitors alone were 
able to decrease the basal expression level of all genes, suggesting the inhibition of endogenous 
TGF-β1 signalling (Fig. 5). This effect was not clear for the primary HSCs, where the gene ex-
pression values of the SB52-treated cells were comparable to the values of the control (Fig. 6). 
In primary HSC, SB52 led to an increase in expression of PDGF receptors A and B, indicating a 





TGF-β1 guides HSCs towards a fibrogenic phenotype 
Transforming growth factor-β1 (TGF-β1) is known to act as a key regulator in chronic liver dis-
eases, and is considered the major pro-fibrotic cytokine in the liver [6] . In our study, TGF-β1 
played a crucial role in the trans-differentiation of both primary and hTERT-HSC into a αSMA-
positive myofibroblasts-like cell type (Fig. 1 C-D, Fig. 4). This effect is specifically dependent from 
the TGF-β1 pathway, since it involves the Smad proteins as demonstrated by the loss of αSMA 
production in presence of the Smad inhibitors SB43 or SB52. As expected, only in a small per-
centage of untreated-cells or SB-treated cells the antibody staining revealed the presence of 
stress fibres, while αSMA expression and its organization into stress fibres were highly repre-
sented in TGF-β1-treated cells. TGF-β1 also increased the mRNA levels for Lysyl Oxidase (Lox) 
family genes, which are markers for activated HSC (Fig. 5-6) [21] . TGF-β1 triggered the gene 
expression of pro-fibrotic proteins, which leads to the remodelling of the ECM and ultimately to 
liver fibrosis (Fig. 5-6). Upregulation of collagen types I and IV, fibronectin and CD44 was in fact 
detected following TGF-β1 treatment. TGF-β1 likewise enhanced the expression of Snail1, beta 
catenin (CTNNB1) and Metalloproteinase 2 (MMP2), which are involved in the epithelial to mes-
enchymal transition and in remodelling of ECM, respectively (Fig. 5-6) [22, 23] . Both hTERT and 
primary HSCs reacted similarly to TGF-β1 exposure in terms of cell activation, suggesting that 
this used HSC cell line may be a suitable model to study TGF-β1-induced HSC activation, as 
being characterized by a quiescent phenotype as shown by low presence of αSMA prior induction.    
In addition, we showed for the first time the effect of TGF-β1 on proliferation and migration of 
primary HSCs. TGF-β1 had no significant effect on the proliferation of primary HSC (Fig. 2 B), as 
previously reported by Yang C et al. for rat primary HSC and LX2 cell line [24] . Interestingly, we 
showed a decrease of cell proliferation through TGF-β1 treatment, in a dose dependent manner 
on the hTERT-HSC after 48 hours (Fig. 2 A). Analogue observations were only found with rat 
HSC, for which thymidine incorporation assays showed a decrease of growth following TGF-β1 
treatment [25] , and the anti-proliferative effect of TGF-β1 on smooth muscle cells and epithelial 
cells is well documented [26–29] . The antiproliferative effect on hTERT-HSC could be due to an 
alteration of non-Smad pathways, such as the upregulation of cyclin-dependent kinase inhibitors 
including p15, p21 and p27 showed for epithelial cells [29] . Additional experiments would be 
required to clarify this point. 
HSC activation also leads to migration and TGF has been shown to either a positive or negative 
role in the migration of cancer cells [30] . It has been shown that TGF-β1 induces cell migration 
of rat primary HSC and LX2 through a polycarbonate membrane, but no data are available for 
hTERT-HSC or human primary HSC [24] . In our hands, TGF-β1 did not induce any significant 




occurring during activation of the HSC, did not allow the cells to migrate in a significantly different 
way than the negative control.  
PDGF-AB drives HSCs towards a mitogenic phenotype  
PDGFs are key regulators of critical biological and pathological functions including tissue remod-
elling, scarring and fibrosis [31] . PDGF isoforms have been shown to act as potent activators of 
fibroblast proliferation, migration and survival [17, 32] . As expected, a significant increment of 
cell growth and migration was observed following PDGF-AB treatment for 48 hours in both primary 
and hTERT-HSCs (Fig. 2 and 3). As previously reported [17] , PDGF affected both proliferation 
and migration of HSCs, but no significant changes were seen in the activation markers (such as 
protein level of αSMA and mRNA levels of Lox genes) and ECM component genes in both HSCs 
(Fig. 1, 5 and 6).  
Furthermore, while PDGF receptor expression is low in healthy liver, increased expression has 
been shown in HSCs during injury [11] . Depletion of PDGFRB in HSCs led to the decrease of 
injury and fibrosis, while its activation accelerated fibrosis [33] . Recent studies have also high-
lighted the involvement of PDGFRA in HSC activation [34] . Here, we have shown an increase in 
the gene expression of both PDGF receptors A and B through SB52 treatment (Fig. 6 F). These 
data suggest the interconnection between the TGF-β1 and PDGF pathways, as recently sug-
gested from other studies [13] . The presence of SB52 could in fact inhibit the Smad signalling 
coming from autocrine TGF-β1, resulting into a more mitogenic phenotype (with increase expres-
sion of PDGF receptors) rather than an activated phenotype. This led us to the hypothesis that a 
combination of more cytokines is required to fully characterize HSC activation in vitro, in order to 
mimic the complex immunoresponce occurring during liver injuries in vivo. 
TGF-β1 and PDGF-AB synergize to promote HSC migration and activation 
TGF-β and PDGF signalling pathways transmit extracellular stimuli into gene transcription, pro-
moting HSC activation under pathological conditions [12] . These two signalling pathways are 
functionally divergent; PDGF promotes proliferation and migration of HSCs, while TGF-β induces 
trans-differentiation of quiescent HSCs into myofibroblasts [6] . Recent data suggested a cross-
talk between them [12, 13] . For instance, PDGFRA has been shown to be required for Smad-
dependent TGF-β signalling, acting as a working partner of TGF-β receptor II [13] . The data 
obtained in our work confirm the presence of some interconnection of the two pathways. In par-
ticular, our data show that in order to achieve a fully activated phenotype, HSCs require both 
stimuli. Specifically, αSMA expression and mRNA levels of several activation markers (MMP2, 
Snail1 and Collagen IV), were increased after co-stimulation with TGF-β1 and PDGF-AB. PDGF-
AB played a dominant role in the increase in proliferation and migration of the HSCs, while TGF-




Taken together, our data demonstrate that PDGF-AB and TGF-β1 synergize leading to full HSC 
activation, characterised by increase in proliferation, migration and activation, suggesting that 
both independent pathways converge and represent key events leading to HSC activation in vitro. 
The data also suggest that a possible therapeutic strategy to promote liver regeneration/repair 
without inducing fibrosis may include the promotion of PDGF-dependent cell proliferation and 
migration together with a repression of TGF-β1-mediated fibrogenesis. 
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Fig. 1. Effect of TGF-β1 and PDGF-AB on HSC activation and viability. (A-B) Seven concen-
trations of TGF-β1 (0-20 ng/mL) (A) and PDGF-AB (0-20 ng/mL) (B) were selected and CCK-8 
assay was performed to assess cytotoxicity on hTERT-HSC after 24 hours, 48 hours and 7 days. 
The absorbance was measured at 450 nm with FlexStaion 3 Reader and the values were nor-
malized with the CyQUANT assay. Values are expressed as percentage of control (mean ± SD, 
N = 3). (C-D) hTERT-HSC cells (C) and human primary HSCs (D) were treated for 48 hours with 
TGF-β1 (1 ng/mL), SB43 (10 μM), SB52 (1 μM) and/or PDGF-AB (5 ng/mL). After treatment, the 
cells were fixed and stained against αSMA (green) and nuclei (DAPI, blue in C and Propidium 
iodite, red in D). The results show an increase in αSMA production after TGF-β1 exposure. SB43 
and SB52 significantly inhibited the TGF-β1-induced αSMA. Pictures taken using fluorescence 





Fig. 2. Effect of TGF-β1 and PDGF-AB on HSC proliferation. hTERT-HSCs (A) and primary 
HSCs (B) were exposed to TGF-β1 and/or PDGF-AB for 48 hours. EdU was added during the 
last 30 hours and detected as described in material and methods. The pictures were taken with 
10X magnification by using confocal microscopy and nuclei were counted with Image J software. 
Values are expressed as percentage of control (mean ± SD). **, P ≤ 0.01; *** P ≤ 0.001 vs control. 
N = 5 for hTERT-HSC (A) and N = 5 different batches (with 5 replicates each) for primary HSC 
(B). 
 
Fig. 3. PDGF-AB-dependent cell migration on HSC. hTERT-HSCs (A) and primary HSCs (B) 
were seeded into the Culture Insert 2-Well (Ibidi) and exposed to TGF-β1 (1 ng/mL), SB52 (1 μM) 
and/or PDGF-AB (5 ng/mL) for 48 hours. Pictures were acquired with 4X magnification every hour 
for a period of 48 hours using Olympus cellVivo incubation system. Pictures of treated and un-




are showed for primary HSCs (B). Migration area was calculated with MRI wound healing tool of 
Image J software and expressed as fold change of the treated vs control (mean ± SD). *, P ≤ 
0.05; **, P ≤ 0.01 vs control. N = 3 for hTERT-HSC (A) and N = 3 different batches (with 2 repli-
cates each) for primary HSC (B). 
 
Fig. 4. Immunohistochemical analysis of αSMA during the wound healing process. A wound 
in hTERT-HSC cells was generated by using Culture-Insert 2 Well  and cells were exposed to 
TGF-β1 and/or PDGF-AB for 48 hours. Immunostaining for αSMA (green) and nuclei (blue) was 
performed and pictures of the wound area were acquired using fluorescence microscopy. (A) 
Control cells did not show high migration rate as well as low level of αSMA. (B) TGF-1 did not 
influence the migratory capacities of HSCs, while significantly induced αSMA production. (C) 
PDGF-AB leads to widespread migration and no increase in αSMA-positive cells. (D) The combi-
nation of both TGF-β1 and PDGF-AB elicited cell migration with a concomitant production of 





Fig. 5. Gene expression of HSC activation and fibrotic markers of hTERT-HSCs exposed 
to TGF-β1, SB43, SB52 and/or PDGF-AB. The cells were exposed to 0.5-1 ng/mL TGF-β1, 10 
μM SB43, 1 μM SB52 and/or 1-5 ng/mL PDGF-AB for 48 hours. In the co-stimulation 1 and 5 
ng/mL were used for TGF-β1 and PDGF-AB respectively. mRNA was extracted using TRIzol 
conventional procedure and fold induction were calculated as 2^(-ΔΔCT) for each sample and 
control and expressed as mean fold induction ± SD of three replicates. Beta-2-microglobulin 
(B2M) was used as reference gene for each sample.  (A) Collagen I (black) and Collagen IV 
(grey); (B) Fibronectin (black) and MMP2 (grey); (C) αSMA  (black) and Snail1 (grey); (D) CD44 





Fig. 6. Gene expression of HSC activation and fibrotic markers of human primary HSCs 
exposed to TGF-β1, SB52 and/or PDGF-AB. The cells were exposed to 1 ng/mL TGF-β1, 1 μM 
SB52 and/or 5 ng/mL PDGF-AB for 48 hours. mRNA was extracted using TRIzol conventional 
procedure and fold induction were calculated as 2^(-ΔΔCT) for each sample and control and ex-
pressed as mean fold induction ± SD of three replicates. Beta-2-microglobulin (B2M) was used 
as reference gene for each sample. (A) Collagen I (black) and Collagen IV (grey); (B) Fibronectin 
(black) and MMP2 (grey); (C) αSMA  (black) and Snail1 (grey); (D) CD44 (black) and Lox (grey); 
(E) CTNNB1 (black) and Loxl2 (grey); (F) PDGFRA (black) and PDGFRB (grey). *, P ≤ 0.05; **, 
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Aims: Elucidate the potential role of Nrf2 pathway in HSC trans-differentiation involved in the 
development of fibrosis. 
Results: Nrf2 depletion induces HSC activation, as shown by an increase in αSMA-positive cells 
and by gene expression induction of ECM components in a TGF-β1/Smad-dependent manner.  
Conclusion: These data indicate that Nrf2 limits HSCs activation, through the inhibition of the 
TGF-β1/Smad pathway in both primary and immortalised HSCs.   
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Hepatic stellate cells (HSC) orchestrate the deposition of extracellular matrix (ECM) and are 
the primary effector of liver fibrosis. Several factors, including TGF-β1, PDGF and oxidative 
stress, have been shown to trigger HSC activation. However, the involvement of cellular 
defence mechanisms, such as the activation of antioxidant response by Nrf2/Keap1 in the 
modulation of HSC activation is not known. The aim of this work was to elucidate the role of 
Nrf2 pathway in HSC trans-differentiation involved in the development of fibrosis. To this 
end, we repressed Nrf2 and Keap1 expression in HSC with specific siRNAs. We then 
assessed activation markers, as well as proliferation and migration, in both primary and 
immortalised human HSCs exposed to Smad inhibitors (SB-431542 hydrate and SB- 
525334), TGF-β1 and/or PDGF. Our results indicate that knocking down Nrf2 induces HSC 
activation, as shown by an increase in αSMA-positive cells and by gene expression induc- 
tion of ECM components (collagens and fibronectin). HSC with reduced Nrf2-levels also 
showed an increase in migration and a decrease in proliferation. We could also demonstrate 
that the activation of Nrf2-deficient HSC involves the TGF-β1/Smad pathway, as the activa- 
tion was successfully inhibited with the two tested Smad inhibitors. Moreover, TGF-β1 elic- 
ited a stronger induction of HSC activation markers in Nrf2 deficient cells than in wild 
type cells. Thus, our data suggest that Nrf2 limits HSCs activation, through the inhibition 
of the TGF-β1/Smad pathway in HSCs.  
 
        Introduction 
Hepatic fibrosis is a scarring process in response to chronic liver injury, and it is charater-
ized by an accumulation of fibrillar extracellular matrix (ECM) [1]. Following liver injury, 
hepatic stellate cells (HSCs) undergo activation, a cellular process during which HSCs 
trans- differentiate into myofibroblasts-like cells [1]. Activated HSC have been recognized 
as the responsible cells for most of the excess of ECM components in chronic liver fibro-
sis [1]. 
HSC activation is triggered by several cytokines; in particular platelet-derived growth fac-
tor (PDGF) and transforming growth factor-β1 (TGF-β1), released from platelet and Kup-
ffer cells respectively, have been identified as the main mitogenic and pro-fibrotic media-
tors for HSCs [1]. 
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Increasing evidence has shown that oxidative stress may promote fibrosis and HSC activation in 
the human liver and rodents [2,3]. In many cell types the transcriptional response to oxidative 
stress is mediated by a cis-acting element termed antioxidant response element (ARE); the nu-
clear factor E2-related factor 2 (Nrf2) has been identified as the most important transcription factor 
acting on the ARE for many genes [4–6]. In the human genome, Nrf2 reg- ulates the transcription 
of more than 500 genes, most of which have a cytoprotective role [6]. 
A key element for the regulation of the activity of Nrf2 is the Kelch-like ECH-associated protein 
1 (Keap1), which acts as a constitutive repressor of Nrf2 [4]. Under normal conditions, Nrf2 is bound 
to Keap1, which is an adaptor molecule for the Cullin3-based E3 ubiquitin ligase complex, leading to 
the degradation of Nrf2 via the by ubiquitin-proteasome pathway [5]. In this condition, Nrf2 appears 
as a highly unstable protein with a half-life of around 15 minutes [4]. Oxidative or electrophilic 
stress causes the inactivation of Keap1, resulting in Nrf2 stabili- zation, nuclear translocation and 
subsequent gene induction [5]. 
Among other organs, Nrf2 plays a predominant role in the liver, since it is a key regulator of the 
constitutive and inducible expression of some phase II and III detoxification enzymes and antioxi-
dant proteins, such as those involved in glutathione synthesis, in primary hepato- cytes and 
hepatocyte-like cells [7]. Several studies reported that Nrf2-knockout mice showed an exacerbated 
cytotoxicity to acetaminophen (APAP) as well as a strongly aggravated liver damage after treat-
ment with CCl4 or ethanol [8–11]. In a similar study, Okawa et al. showed that Keap1-knockout 
mice were significantly more resistant to APAP than control animals [12]. Concordantly, experi-
ments in mice showed an increase in nuclear translocation of Nrf2 after APAP administration [13]. 
In addition to its protective role, it has been demonstrated that Nrf2 regulates hepatocyte prolifera-
tion by ensuring normal insulin/IGF-1 and Notch1 sig- nalling during liver regeneration [14,15]. 
Recently, we showed upregulation of both Nrf2 and Keap1 after Methotrexate- and Thioacetam-
ide- induced fibrosis in a 3D human cell culture model, indicating a role of Nrf2 in hepatic fibrosis 
[16]. Nrf2 has been shown to have antifibro- tic effect in liver, lung and kidney, by promoting the 
dedifferentiation of fibroblasts [17–19]. 
Many studies have been conducted on Nrf2-related effects on liver but little is known about its 
role on HSCs. It has been reported that Nrf2 inhibits the TGF-β1-dependent expression of fibrosis 
markers in a human stellate cell line [17]. Yang et al. have shown that TGF-β1 reduced the pres-
ence of Nrf2 in a rat hepatic stellate cell line [3]. This effect was dependent on the epi- genetic 
regulation operated by the microRNA-200a. However, although these studies suggest an involve-
ment of Nrf2 in HSC activation, studies conducted on human primary HSCs are still lacking. Here, 
we report the effects of Nrf2-knockdown on proliferation, migration and activation of human HSCs. 
Our studies demonstrate that Nrf2-knockdown induces HSC acti- vation in both human primary 
and immortalised (hTERT) HSCs. Moreover, this activation can be modulated by TGF-β1, PDGF-
AB and/or Smad inhibitors. These results may contrib- ute towards studying and developing new 
successful and advantageous therapies for liver fibrosis. 
 
 
Material and methods 
Reagent, chemicals and antibodies 
DMEM High Glucose (41965; Invitrogen), Fetal Bovine Serum (FBS) (10270; Invitrogen), Peni-
cilin-Streptomycin (A8943; Applichem), TGF-β1 (T5050; Sigma), PDGF-AB (P8147; Sigma), SB-
431542 hydrate (SB43) (S4317; Sigma), SB-525334 (SB52) (S8822; Sigma), Triton X-100 (T8787; 
Sigma), Bovine serum albumin (BSA) (05473; Fluka), Lipofectamine1 RNAiMAX Transfection 
Reagent (13778030; Thermo Fisher), OptiMEM (51985034; Thermo Fisher), αSMA antibody 
(A5228; Sigma), secondary antibodies Alexa Fluor1 488 (A11017 and A11078; Invitrogen), DAPI 
(D9542; Sigma), Propidium Iodide (7109; Sigma), anti-β-Actin antibody (sc-47778; Santa Cruz 
Biotechnology), anti-Nqo1 antibody (Ab2346; Abcam), anti- Nrf2 antibody (16396-1-AP; Pro-
teintech), Anti-α-Tubulin antibody (T8203; Sigma), anti- Keap1 antibody (10503-2-AP; Pro-
teintech), Anti Mouse-AP (4760.1; Roth), Anti-Rabbit Per- oxidase antibody (A6154; Sigma), Anti-
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Cell culture and treatments 
Human primary HSCs were purchased from iXCells Biotechnologies, USA, (Cat. 10HU-210) or 
Innoprot, Spain (Cat. P10653). They were cultured in DMEM High Glucose supplemented with 
10% FBS and 1% Penicillin-Streptomycin (complete DMEM) and used up to 5 passages. hTERT-
HSC were kindly provided by Dr. Bernd Schnabl (UC San Diego, USA)[20] and were cultured in 
complete DMEM up to 12 passages. The cells were kept in the humidified incuba- tor at 37˚C 
with 5% CO2. Cell treatments were performed in serum-free medium for a maxi- mum of 48 
hours without changing the medium. Following concentration were used as indicated in the leg-
end: 0.5–10 ng/mL TGF-β1, 1–5 ng/mL PDGF-AB, 10 μM SB43, 1 μM SB52. 
 
Nrf2 and Keap1 knockdown 
A number of 1.9 x 105 HSCs per well were seeded in 12-well plates. The cells were transfected at 
day zero with siPOOL5 targeting human NFE2L2 (Nrf2) (NM_001145412; siTOOLs Bio- tech) 
and human Keap1 (NM_012289; siTOOLs Biotech). Briefly, a mixture containing siR- NAs and 
Lipofectamine was prepared in OptiMEM and added into the well at 1:10 dilution in complete 
DMEM, in order to achieve a final concentration of 5 nM siRNA and 2 μL Lipofecta- mine per well. 
The cells were transfected for 72 hours and then detached and used for the next experiments. 
Scrambled siRNAs were purchased by siTOOLs Biotech and used as negative control (indicated 
as siCON from now). 
 
Immunocytochemistry analysis 
After different treatments, HSCs were fixed in 4% formaldehyde for 15 minutes, followed by per-
meabilization with 0.1% Triton-X-100 for 20 minutes. Blocking was performed with 1% BSA in 
PBS for 60 minutes, followed by incubation with primary antibody against αSMA (dilution 1:200 in 
blocking solution) or Nqo1 (1:500) for 90 minutes. Incubation with second- ary antibody was per-
formed for 60 minutes in blocking solution at a 1:400 dilution. All steps were conducted at room 
temperature. DAPI and Propidium Iodide were used to stain the nuclei. 
 
Click-iT EdU proliferation assay 
The Click-iT1 EdU Alexa Fluor1 488 Imaging Kit (C10637; Invitrogen) was used to measure the 
proliferation rate of the cells after treatments. After cell transfection, the cells were detached and 3 
x 104 cells/cm2 were seeded in 96-well plate format. After overnight attach- ment, the cells were 
treated with EdU for 30 hours. In a separate experiment, detached cells were seeded and immedi-
ately treated with 0.5–1 ng/mL TGF-β1, 1–5 ng/mL PDGF-AB and a mixture with 1 ng/mL TGF-β1 
and 5 ng/mL PDGF-AB for 48 hours. EdU dye was added only during the last 30 hours of each 
experiment and detected following manufacturer’s instruc- tions. The pictures were acquired with 
the Olympus Laser Confocal Scanning Microscope FV1000D spectral type (inverted microscope 
IX81) and analysed with ImageJ to determinate the proliferation rate. 
 
Gene expression analysis 
To determinate the efficiency of transfection, as well as the activation profile of the HSCs, RNA 
from treated and untreated cells was isolated following TRIzol extraction procedure. RNA was 
reverse transcribed using a reverse transcriptase (Promega) and oligo dT (Qiagen) and real time 
PCR was performed using FastStart TaqMan Mix (Roche) and TaqMan probes from Invitrogen. 
Real time, Taqman qPCR was performed on selected genes (see Table 1). The following qRT-
PCR Program was used: 10 minutes denaturation at 95˚C, followed by 40 cycles of 15 seconds at 
95˚C and 1 minute at 60˚C. The Ct values were assessed using the Corbett Rotorgene Analysis 
Software 6000, and B2M was used as an internal standard for the normali- zation of the fold 
changes of each gene of interest (GOI). Heat map for each gene and condi- tion was obtaining 
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The migratory capacity of HSCs was investigated using the Culture-Insert 2 Well (80209; Ibidi) 
according to the manufacturer’s instructions. Briefly, 70 μL of 3 x 105 cells/mL suspen- sion were 
incubated in each chamber in serum-free medium overnight. After cell attachment, the culture 
insert was gently removed by using sterile tweezers, leaving a cell-free gap of approximatively 
500 μm. Medium was slowly aspired and 1 mL/well of serum free DMEM medium was added. 
Migration of transfected HSCs was evaluated in presence of TGF-β1, PDGF-AB and SB52 in-
hibitor. The wound healing process was followed during 48 hours by time laps microscopy, using 
Olympus cellVivo incubation system with 4X magnification. Pic- tures were acquired every hour 
for a period of 48 hours. Pictures were analysed with ImageJ and migration area was calculated 
with MRI Wound Healing Tool (http://dev.mri.cnrs.fr/ projects/imagej-macros/wiki/Wound_Heal-
ing_Tool) as previously published [21]. 
 
 
Table 1. TaqMan probes used for the research. 
 
Gene of interest Abbreviation Invitrogen Ref.nr. 
Beta-2-microglobulin (Housekeeping gene) B2M Hs00187842_m1 
Actin, alpha 2, smooth muscle ACTA2 (αSMA) Hs00426835_g1 
Activating transcription factor 3 ATF3 Hs00231069_m1 
Catenin beta 1 CTNNB1 Hs00355049_m1 
Collagen 1 alpha 1 COL1α1 Hs00164004_m1 
Collagen 4 alpha 1 COL4α1 Hs00266237_m1 
Fibronectin 1 FN1 Hs00415006_m1 
Hyaluronic acid receptor CD44 Hs01075861_m1 
Kelch-like ECH-associated protein Keap1 Hs00202227_m1 
Lysyl oxidase Lox Hs00942480_m1 
Lysyl oxidase like 2 Loxl2 Hs00158757_m1 
Metalloproteinase 2 MMP2 Hs01548727_m1 
Mitogen-activated protein kinase 8 MAPK8 Hs01548508_m1 
Mitogen-activated protein kinase 14 MAPK14 Hs01051152_m1 
NAD(P)H quinone dehydrogenase 1 Nqo1 Hs02512143_s1 
Nuclear factor (erythroid-derived 2)-like 2 NFE2L2 (Nrf2) Hs00975961_g1 
PDGF receptor alpha PDGFRA Hs00998018_m1 
PDGF receptor beta PDGFRB Hs01019589_m1 





The presence of TGF-β1 in the supernatants of transfected HSCs was determined using com- 
mercial human ELISA kit (ABIN1979586; Antibodies-online GmbH), strictly following manu- fac-
turer’s instructions. 
 
Western blot analysis 
Cells were lysed in RIPA lysis buffer (89900; Thermo Fisher) on ice. Whole extracts were pre- 
pared and proteins were quantified by using a standard Bradford assay. 30 μg of proteins were 
separated by SDS-PAGE on Biorad precast anykD gel (456–9033; Biorad) and then blotted onto 
a nitrocellulose membrane (GE10600004; Sigma). After 60 minutes blocking with Odys- sey1 
Blocking Buffer (PBS) (927–40000, LI-COR), the membranes were incubated overnight with pri-
mary antibodies diluted in blocking buffer as following: anti-β-Actin antibody (1:500), anti-Nqo1 
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For Nrf2 detection blocking overnight was performed, followed by overnight incubation with anti-
Nrf2 antibody (1:750). Horseradish peroxidase conjugated anti-mouse, anti-rabbit and anti-goat 
antibodies were used as secondary antibodies for 60 minutes in blocking buffer at the dilution of 
1:5000. After extensive washing in PBS-T, the membranes were developed by incu- bating for 10 
minutes in presence of BCIP and NBT in AP-buffer, and intensities quantified using Image J anal-
ysis software as previously published [22]. 
 
Statistical analysis 
Experiments with primary HSC were conducted with at least 3 batches of cells as indicated in the 
legend. Data were analysed using GraphPad Prism 7 (GraphPad Software, inc.) and expressed 
as mean values ± SD as indicating in the legend. The Student’s t-test was used for comparison 
between two groups. Data from three or more groups were analysed by one-way analysis of vari-




Exposure to TGF-β1 suppresses gene expression of Nrf2 and re-
lated genes 
Based on our own and previously published data [1,16,23], we exposed the HSCs to TGF-β1 in 
order to induce HSC activation. At all tested TGF-β1 concentrations, gene expression levels of 
Nrf2, Keap1 and Nqo1 were significantly downregulated in immortalized HSC (hTERT-HSC) after 
48 hours of treatment (Fig 1A). Nrf2 mRNA levels were downregulated in a concentra- tion-de-
pendent manner already after 24 hours (S1A Fig), while Nqo1 showed a significantly downregu-
lation only after 48 hours of exposure (Fig 1A and S1C Fig). Downregulation of Keap1 was ob-
served at all three concentrations of TGF-β1 and at all time points (except 1 ng/ mL at 24 hours) 
(Fig 1A and S1B Fig). In primary HSC, TGF-β1 significantly decreased the mRNA levels of both 
Nrf2 and Nqo1after 48 hours of exposure, but no change in expression was observed for Keap1 
(Fig 1B). The downregulation of Nrf2 and Nqo1 by TGF-β1 could be prevented by the Smad inhibi-
tor SB52. This inhibitor led to the upregulation of the mRNA lev- els of both Nrf2 and Nqo1, even 
when applied in combination with TGF-β1, supporting a direct link between TGF-β1 stimulation 
and Nrf2-repression (Fig 1B). 
In addition to the analysis of the mRNA levels of selected markers, we determined the pro- tein 
levels of Nrf2, Keap1 and Nqo1 after exposure of HSCs to TGF-β1 (Fig 1C–1F). Both human 
immortalised and primary HSCs (Fig 1C and 1D), showed high basal levels of Nqo1. The down-
regulation of Nrf2 mRNA caused by exposure to TGF-β1 did not lead to any significant changes 
in its protein levels at 24h. On the contrary, Nrf2 levels were slightly increased by 1 ng/mL TGF-
β1 at 48 hours in both HSCs. An increase in the protein levels of Keap1 was observed after treat-
ments with TGF-β1 in hTERT-HSC in a concentration depen- dent manner at both 24 and 48 
hours exposure (Fig 1E). Lower levels of Keap1 were observed in primary HSC compared to 
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Fig 1. TGF-β1 suppresses mRNA expression of Nrf2 in HSCs. (A) hTERT-HSCs were exposed to 1–5 ng/mL TGF-β1 for 48 hours. mRNA 
was extracted using TRIzol conventional procedure and fold changes were calculated as 2^(-ΔΔCT) for each sample and control and expressed 
as mean fold change ± SD (N = 3). Beta- 2-microglobulin (B2M) was used as reference gene for each sample. The results show a significant 
downregulation of Nrf2, Keap1 and Nqo1 after exposure to TGF- β1. (B) Primary HSCs were exposed to 1 ng/mL TGF-β1, 1 μM SB-525334 
(SB52) and/or 5 ng/mL PDGF-AB for 48 hours. mRNA was extracted using TRIzol conventional procedure and fold changes were calculated 
as 2^(-ΔΔCT) for each sample and control and expressed as mean fold change ± SD (N = 3 different batches). Beta-2-microglobulin (B2M) 





SB52 induces upregulation of Nrf2 and Nqo1, efficiently inhibiting the TGF-β1 effect. (C-D) The protein levels of Nrf2, Nqo1 and actin beta were 
analysed by Western blot analysis after exposure to 0–10 ng/mL TGF-β1 in hTERT-HSC (C) and primary HSCs (D) for 24 and 48 hours. (E-F) 
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The protein levels of Keap1 and Tubulin were analysed by Western blot analysis after exposure to 0–10 ng/mL TGF-β1 in hTERT-HSC (E) and 






Nrf2 knockdown induces stellate cell activation 
To further investigate the role of Nrf2 in HSC activation, we performed the knockdown of Nrf2 or 
Keap1 on HSCs using specific siRNAs (siNrf2 and siKeap1). After 72 hours of incuba- tion with 
siRNA, we could detect an efficient knockdown in both primary and immortalised HSCs: mRNA 
of Nrf2 and Nqo1 were significantly downregulated by 80–90% in both primary and hTERT-HSCs 
after siNrf2 (Fig 2A and 2B). Protein levels were visualised by western blot in hTERT-HSC, show-
ing a successful knockdown also at the protein level (Fig 2C). In addi- tion, immunostaining of 
Nqo1 in hTERT-HSC confirmed the downregulation after exposure to siNrf2 (Fig 2D). The knock-
down was maintained for up to 7 days after transfection (data not shown). As expected, siKeap1 
induced downregulation of Keap1 mRNA, and a concomi- tant upregulation of Nqo1 mRNA and 
protein (Fig 2A–2C). In particular, mRNA levels of Nqo1 were upregulated by 4.8- and 3.2-fold 
changes after siKeap1 in hTERT-HSC and pri- mary HSC, respectively. 
Transfection of both immortalised and primary HSCs with siNrf2 caused HSC-activation deter-
mined by transcriptional induction of αSMA, Collagens I and IV, and TGF-β1 (Fig 3A and 3B, 
respectively). Lox, loxl2 and PDGFRB were also upregulated in human primary HSCs (Fig 3B). No 
significant changes were seen in both scrambled control (siCON) and siKeap1 HSCs. Secreted 
TGF-β1 was also significantly increased in primary HSC from 20 to 70 pg/mL after siNrf2 transfec-
tion (Fig 3E). Additional evidence for the activation of HSCs by siNrf2 is provided by the strong 
upregulation of αSMA and its organization into stress fibres (Fig 3C and 3D). This effect was 
inhibited by the Smad inhibitors SB43 and SB52, indicating an involvement of the TGF/Smad 
pathway. In this experimental set up, stronger inhibition was observed with SB43 rather than 
SB52 in both primary and immortalised HSCs. As expected, PDGF-AB did not affect αSMA pro-
duction, while TGF-β1 further induced αSMA and stress fibres formation in a Smad-dependent 
manner, as indicated by the immunostaining in pres- ence of TGF-β1 and/or SB inhibitors (Fig 3C 
and 3D). Interestingly, siKeap1 showed a protec- tive effect against TGF-β1-induced αSMA pro-
duction compared to negative control in primary HSCs, suggesting a protective role of Nrf2 
against TGF-β1-induced HSC activation (Fig 3F). 
 
Nrf2 knockdown reduces cell proliferation and increases 
PDGF-induced proliferation rate in HSCs 
To explore the proliferative capacities of the transfected HSCs, we performed an EdU prolifer- ation 
assay (Fig 4). The proliferation rate was around 0.7 for parental hTERT-HSC, and around 0.6 for 
parental primary HSC. In both HSCs, siNrf2 significantly reduced the prolifera- tion rate by around 
30% (Fig 4A and 4B). siCON and siKeap1 did not affect the proliferation rate in the primary HSCs, 
while they significantly reduced the proliferation in the hTERT- HSC. Nrf2 knockdown cells 
showed more PDGF-AB-induced cell proliferation than siCON cells (Fig 4C and 4D). Proliferation 
was in fact increased by 50–100% in both siNrf2 HSCs after exposure to PDGF-AB compared to 
siCON HSCs where only an increase of 25% was detected. These results suggest that Nrf2 
knockdown might drive the cells towards activation, making them more sensitive to stimuli. TGF-
β1 did not affect the proliferation rate in primary HSCs, neither with siCON nor with siNrf2 (Fig 
4D), while downregulation was measured in hTERT-HSC, with a more pronounced effect after 
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Fig 2. siRNA knockdown of Nrf2 pathway-related genes. (A-B) siRNAs for Nrf2 (siNrf2), Keap1 (siKeap1) and scrambled (siCON) were used 
to knockdown Nrf2 and Keap1 in hTERT-HSC (A) and primary HSC (B). mRNA level of Nrf2, Keap1 and Nqo1 were then analysed, showing 
an efficient knockdown of both Nrf2 and Keap1. Fold changes were calculated as 2^(-ΔΔCT) for each sample and control and expressed as 
mean fold change ± SD. *, P ≤ 0.05; **, P ≤ 0.01; ***; P ≤ 0.001 vs siCON (mean ± SD, N = 4 from independent experiment for hTERT-HSC 
and N = 6 different batches in primary HSC). (C) Protein levels of Nrf2, Keap1 and Nqo1 were analysed by Western blot in knockdown 
hTERT-HSC. Ctrl: control samples; siCON: scrambled siRNA; siNrf2: Nrf2 knockdown; siKeap1: Keap1 knockdown. Protein were extracted 72 
hours after the transfection. (D) Immunocytochemistry analysis of Nqo1 in hTERT-HSC. Green: Nqo1. siCON: scrambled siRNA; siNrf2: Nrf2 






Knockdown of Nrf2 induces cell migration in HSCs 
Nrf2 knockdown induced a significant increase in cell motility in both hTERT-HSC and pri- mary 
HSCs while Keap1 knockdown induced a decrease in the migration rate only in primary HSCs 
(Fig 5). In particular, siNrf2 hTERT-HSC displayed 1.5-fold higher migration than con- trol cells at 
both 24 and 48 hours (Fig 5A); no changes were measured after siKeap1 and siCON. Primary 
HSCs showed higher migration than hTERT-HSC, with a complete repair of the wound after 24 
hours (data not shown). Thus, the migration rate was calculated at 12 and 24 hours for primary 
HSCs (Fig 5B). Similarly, to hTERT-HSC, siNrf2-treated primary HSCs displayed higher migra-
tion than control cells at 12 hours; no significant changes were mea- sured at 24 hours. The 
motility of knockdown cells was further affected by TGF-β1 and PDGF-AB (Fig 5C). In fact, 
transfected primary HSCs showed a PDGF-AB-induced cell migration in both siCON and siNrf2 
cells with a synergistic effect of TGF-β1 and PDGF-AB (Fig 5C). TGF-β1 did not affect the migra-
tion of control cells (siCON), while a decrease in migration was displayed in the Nrf2 knock-
down cells, indicating a stronger response of the cells to the cytokine. No significant effect of 
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Fig 3. Effect of Nrf2 knockdown on HSC activation and response to stimuli. (A-B) After 72 hours knockdown with siRNAs, mRNA was 
extracted from hTERT-HSC cells (A) and human primary HSCs (B). Fold change for each gene of interest was calculated as 2^(-ΔΔCT) for 
each sample and control and expressed as mean fold change ± SD. Beta-2-microglobulin (B2M) was used as reference gene for each sample. 
*, P ≤ 0.05; **, P ≤ 0.01; ***; P ≤ 0.001 vs Control (mean ± SD, N = 4 from independent experiment for hTERT-HSC and N = 6 different 
batches for primary HSC). (C-D) hTERT-HSCs (C) and primary HSCs (D) were treated for 48 hours with TGF-β1 (1 ng/mL), SB431542 hydrate 
(SB43) (10 μM), SB-525334 (SB52) (1 μM) and/or PDGF-AB (5 ng/mL). After treatment, the cells were fixed and stained against αSMA (green 
in C and red in D) and nuclei (DAPI, blue). The results show an increase in αSMA production in Nrf2 knockdown cells and a further increase 
after TGF-β1 exposure. SB43 and SB52 significantly inhibited the TGF-β1-induced αSMA. Pictures taken using fluorescence microscopy. 
siNrf2: Nrf2 knockdown. Scale bar: 100 μm. (E) TGF-β1 release was measured in supernatant medium in both transfected hTERT and 
primary HSCs by ELISA. siCON: scrambled siRNA; siNrf2: Nrf2 knockdown; siKeap1: Keap1 knockdown. *, P ≤ 0.05; **, P ≤ 0.01 vs Control 
or siCON (mean ± SD, N = 4 from independent experiments for hTERT-HSC and N = 5 different batches for primary HSC). (F) Immunostain-
ing of αSMA (red) and nuclei (DAPI, blue) in Keap1 knockdown primary HSCs. Knockdown cells show more resistance again TGF-β1 (1 
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Fig 4. Effect of siRNAs, TGF-β1 and/or PDGF-AB on HSC proliferation. (A-B) hTERT-HSCs (A) and primary HSCs (B) were transfected for 
72 hours with siNrf2, siKeap1 or siCON. Cells were then detached and plated for EdU staining as described in Materials and methods section. 
The pictures were taken with 10X magnification by using confocal microscopy and nuclei were counted with Image J software. siCON: 
scrambled siRNA; siNrf2: Nrf2 knockdown; siKeap1: Keap1 knockdown. *, P ≤ 0.05; **, P ≤ 0.01; ***; P ≤ 0.001 vs control or siCON. Values 
are expressed as rate of proliferation (mean ± SD); N = 4 independent experiment with 5 replicates each for hTERT-HSC, and N = 6 differ-
ent batches with 5 replicates each. (C-D) Proliferation rate of transfected hTERT-HSC (C) and primary HSC (D) after exposure to 0.5–1 
ng/mL TGF-β1 and/or 1–5 ng/mL PDGF-AB for 48 hours. EdU was added during the last 30 hours of the experiment. Values are expressed 
as percentage of proliferation over each control sample. *, P ≤ 0.05; **, P ≤ 0.01; ***; P ≤ 0.001 vs Control (mean ± SD, N = 4 replicates for 




Nrf2 knockdown induces stellate cells activation in a Smad-
dependent manner 
To elucidate the molecular mechanisms underneath the siNrf2-induced HSC activation, we 
exposed the transfected cells to TGF-β1, PDGF-AB and/or Smad inhibitors for 48 hours and 
assessed gene expression of activation and fibrotic markers (Fig 6). In both siCON and siNrf2 
hTERT-HSC, SB43 displayed a strong inhibitory effect and decreased the TGF-β1 elicited acti- 
vation of the cells. The effect of SB52 was similar but less marked. Nrf2 knockdown cells also 
showed higher response to TGF-β1 than siCON cells, leading to a significant upregulation of 
all the markers (except collagens) already at 0.5 ng/mL TGF-β1 (Fig 6B). PDGF-AB slightly in-
duced CD44, Lox genes, CTNNB1, MMP2 and Snail1 only in siNrf2 cells. Consistently, the com-
bination of TGF-β1 and PDGF-AB showed stronger gene expression changes in siNrf2 sam-
ples than siCON samples (Fig 6). Interestingly, SB43 successfully inhibited the TGF-β1-induced 
gene induction, with a weaker effect on the siNrf2 cells. SB52, showed a strong inhibitory effect 
on siCON HSCs, while some of the markers (FN1, CD44, CTNNB1, Lox, Loxl2, MMP2, MAPK8) 
were still slightly upregulated after TGF-β1/SB52 treatments. These data indicate an anti-activa-
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Fig 5. Nrf2 knockdown-dependent migration of HSCs. After 72 hours of knockdown, hTERT-HSCs (A) and primary HSCs (B) were seeded into 
the Culture Insert 2-Well (Ibidi). Pictures were acquired with 4X magnification every hour for a period of 48 hours using Olympus cellVivo incubation 
system. Pictures of the samples at 0, 24 and 48 hours are showed for hTERT-HSC (A), while 0,12 and 24 hours are showed for primary HSCs (B). Mi-
gration area was calculated with MRI wound healing tool of Image J software and expressed as fold change of the treated vs control (mean ± SD). *, P ≤ 
0.05; **, P ≤ 0.01 vs Control. N = 4 independent experiments for hTERT-HSC (A) and N = 6 different batches for primary HSC (B). (C) After transfec-
tion, primry HSCs were seeded into the Culture Insert 2-Well and exposed to TGF-β1 (1 ng/mL), SB-525334 (SB52) (1 μM) and/or PDGF-AB (5 ng/mL) 
for 48 hours. Pictures were acquired with 4X magnification every hour for a period of 48 hours using Olympus cellVivo incubation system. Migration area 
at 12 hours was calculated with MRI wound healing tool of Image J software and expressed as fold change of the treated vs control (mean ± SD). *, P 
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Fig 6. Heat map analysis of gene expression between control and Nrf2 knockdown hTERT-HSC. Heat map analysis showing differential 
gene expression pattern in siCON transfected hTERT-HSC (A) and siNrf2 transfected hTERT-HSC (B) Heat map was generated on -
Log2(ΔΔCT) by using the Heatmapper online software (http://www2.heatmapper.ca/expression/). Columns represent each gene of interest, 






Recently, Nrf2 has drawn attention to its role as an antifibrotic agent in the liver [17]. How- 
ever, although Nrf2 has been identified as an important factor in HSC activation [3], the 
mech- anism through which it acts in HSC remains unclear. In this study, we focused on 
Nrf2 pathway in both quiescent and activated HSC. Both primary and immortalised HSCs 
showed high level of Nrf2 and especially of Nqo1 prior treatments (Fig 1), which is con-
sistent with pre- viously published data on rat HSCs showing high Nrf2 content in quiescent 
cells and lower lev- els after HSCs activation [3]. These high levels of Nrf2 may contribute 
to maintain HSCs in their quiescent phenotype, as shown by the low level of αSMA before 
applying the treatments (Fig 3C and 3D). In our study, we demonstrated that TGF-β1-
induced HSC activation signifi- cantly reduced the mRNA levels of both Nrf2 and Nqo1 in 
a concentration and time-depen- dent manner in human HSCs. However, TGF-β1 expo-
sure did not significantly affect the protein levels of Nrf2 or Nqo1. A potential explanation for 
the changes in the mRNA level may be due to a loss of Nrf2 function rather than a de-
crease in protein quantity. Consistent with this hypothesis, we detected an upregulation of 
ATF3 after TGF-β1 exposure (S1D Fig). It has been reported that TGF-β1-induced ATF3 
binds Nrf2, resulting in a strong repression of an ARE reporter, without directly affecting 
the Nrf2 protein level [24,25]. Nrf2 may also be anchored to the cytoskeleton by Keap1, as 
suggested by the increase in Keap1 protein amount after TGF-β1 exposure (Fig 1E and 
1F). 
Our results strongly support the direct involvement of Nrf2 in limiting HSC activation. We 
could show that decreased levels of Nrf2 induced a significant upregulation of genes in-
volved either in HSC activation (αSMA, Lox, Loxl2) or ECM remodelling (Collagens I and 
IV) (Fig 3A and 3B). The upregulation of TGF-β1 and PDGFRB are relevant hallmarks of 
HSC activation, due to the involvement of these proteins in maintaining a positive loop 
towards activation [23,26]. Primary HSCs displayed a stronger response to siNrf2 based on 
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Decreased levels of Nrf2 in HSC also led to increased production and release of TGF- 
β1-levels suggesting that the HSC activation was at least partly TGF-β1/Smad-depend-
ent. In support of this theory, the two Smad inhibitors SB43 and SB52 efficiently reduced 
the TGF- β1-induced increase in αSMA production and the induction of mRNA levels of 
most of the activation markers in siNrf2 HSCs (Fig 3C and 3D and Fig 6). The less marked 
activation phe- notype observed with the inhibitors alone may be due to the blocking of 
basal activation of the Smad pathway (e.g. through endogenous TGF-ß1). On the other 
hand, Nrf2 accumulation in siKeap1-HSCs led to a milder activation by TGF-β1, based on 
induction of αSMA (Fig 3F). 
These results indicate that the high amount of Nrf2 in quiescent HSCs is essential to main-
tain- ing a repressed phenotype, suggesting a new role of Nrf2 as anti-fibrogenic factor in 
HSCs. 
Migration and proliferation are important hallmarks of activated HSC as well as of can-
cer progression in many tissues, and they have been often related to Nrf2 pathway [1,27–
30]. Here we report that Nrf2 inhibits migration and induces proliferation in quiescent 
HSCs. The deple- tion of Nrf2 significantly increased cell motility, while Keap1 knockdown 
significantly reduced motility in primary HSCs (Fig 5). Cell migration was not correlated to 
cell proliferation, as indicated by the decrease in the proliferation rate of the siNrf2 cells 
(Fig 4). No release of PDGF-AB was detected in either HSCs, indicating that the effects 
on migration and prolifera- tion are not directly correlated to PDGF (data not shown). Simi-
larly, the two Smad inhibitors SB43 and SB52 did not affect neither proliferation nor migra-
tion of HSCs, suggesting a Smad- independent regulatory mechanism of these two cellular 
processes (data not shown). Nrf2 has been shown to interact with the PI3K-AKT signalling 
pathway and NF-kB in regulating anti- oxidant- as well as proliferation- and migration-
related genes in many tissues [31–33]. The antagonistic effect of Nrf2 to NF-kB may be 
one of the mechanisms through Nrf2 inhibits migration and invasiveness in the HSCs, as 
it has been shown for human embryonic kidney cells [33]. Similarly, an interaction with 
AKT may be acting in HSCs and regulates prolifera- tion. AKT has been shown to play an 
important role in the early activation of HSC and in their protection against apoptosis 
[34,35]. On the other hand, the promotion of proliferation oper- ated by Nrf2 may be corre-
lated to its inhibitory effect on the TGF-β1 pathway, as the anti-pro- liferative effect of this 
cytokine has been widely documented on smooth muscle cells and epithelial cells [36–39]. 
Concordantly, our results show that TGF-β1 decreased HSC prolifera- tion of the HSC-line 
and that this response was further enhanced in Nrf2-deficient cells. 
Depletion of Nrf2 also led to a more pronounced PDGF-AB-induced proliferation, 
whereas only minor effects on cell migration were observed (Fig 4C and 4D and Fig 
5C). 
Our evidence provides insight into a novel role of Nrf2 in HSCs. Fig 7 illustrates the Nrf2 
signalling pathway and its interplay with the TGF-β1/Smad pathway. We showed high level 
of both Nrf2 and Nqo1 prior TGF-β1 induction in HSCs. Nrf2, as well as Nqo1, have been 
identi- fied as the most important genes involved in the oxidative response against reac-
tive oxygen species (ROS) [40]. The high amount of Nrf2 in the HSCs may inhibit the 
Smad2/3 protein by inducing the gene expression of phosphatases (such as PPM1A), 
which may reduce the phos- phorylation of Smad2/3 as previously published [41]. This 
would result in a low amount of active Smad2/3, favouring a proliferative status rather 
than the induction of the genes involved in HSC activation and motility. This is concordant 
with the phenotype of control HSCs observed in our experiments, characterized by low 
levels of activation markers (αSMA and TGF-β1). Nrf2 has also been shown to bind Smad 
proteins in cancer cell lines, acting as a tran- scriptional repressor by competing with 
Smad complex for the co-transcriptional activator p300/CBP [27]. These observations 
point out Nrf2 as a key factor in maintaining a repressed phenotype in HSC, which is in 
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Fig 7. Nrf2 intervention into the TGF-β1/Smad signalling pathway. Panel A, basal condition: HSCs express high levels of both Nrf2 and its 
target genes (e.g. Nqo1), thereby controlling reactive oxygen species (ROS) level. Nrf2 also inhibits Smad pathway by binding directly to 
Smad protein or through the action of phosphatases [41]. In these conditions, the TGF-β1/Smad pathway has a low activity, resulting in 
low level of αSMA, collagens and TGF-β1. Thus, HSC cells exhibit a quiescent phenotype. Panel B, Nrf2 knockdown: we have found out 
that Nrf2 knockdown, with a consequent decrease of its target genes, induces stellate cells activation. Decrease in Nrf2 was in fact associ-
ated with an increase in the levels of Extracellular matrix (ECM) components as well as αSMA and TGF-β1. TGF-β1 further induces the ex-
pression of ATF3, which acts as functional repressor of Nrf2. We found out that this siNrf2-induced stellate cell activation may be regulated 




Following Nrf2 knockdown (Fig 7B), Nqo1 levels in the cytoplasm decrease quickly, which 
may result in an increase of ROS and its inhibitory effect of PPM1A [41]. Thus, Smad2/3 
could bind Smad4 and translocate to the nucleus, resulting in a strong induction of HSC 
activation markers, induction of migration and inhibition of proliferation. In line with this 
hypothesis, Smad inhibitors could modulate siNrf2-induced HSC activation, confirming 
the involvement of the TGF-β1/Smad pathway. Interestingly, SB43 showed a stronger 
inhibition than SB52, both alone and in combination with TGF-β1. This may be related to 
their different inhibition mechanism. SB43 has been shown to inhibit the TGF-β type I 
receptor (TβRI), acting more upstream on the pathway compared to SB52, which inhib-
its Smad3 phosphorylation and nuclear translocation [42–44]. Nrf2 knockdown (and 
TGF-β1 release), as well as the addition of exogenous TGF-β1, lead to high amount of 
phosphorylated Smad2/3 which implies SB52 to be ineffective at fully repressing TGF-
β1-induced gene expression. New synthesized ATF3 could further contribute to the Nrf2 
inhibition, exacerbating more the TGF-β1-induced HSC activation. 
In conclusion, our data provide clear proof of the direct involvement of Nrf2 in HSC acti-
vation. This underlines the importance of Nrf2 in non-parenchymal liver cells in addition 
to its already known cytoprotective role in hepatocytes. Our data also provide insights 
into the mechanisms by which Nrf2 decreases HSC activation, highlighting a new role of 
Nrf2 as anti- fibrotic molecule in HSCs. Indeed, the depletion of Nrf2 may be a contributing 
factor to HSC activation in vitro as well as in vivo. Intervention on Nrf2 pathway in HSC 
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S1 Fig. TGF-β1 effects on Nrf2 pathway’s component. (A-C) hTERT-HSCs were exposed 
to 1–5 ng/mL TGF-β1 for 24, 48 and 72 hours. mRNA was extracted using TRIzol conven-
tional procedure and fold changes were calculated as 2^(-ΔΔCT) for each sample and 
control and expressed as mean fold change ± SD (N = 3). Beta-2-microglobulin (B2M) was 
used as refer- ence gene for each sample. The results show a significant downregulation of 
Nrf2, Keap1 and Nqo1 after exposure to TGF-β1 in a time- and concentration-dependent 
manner. (A) Nrf2 mRNA levels; (B) Keap1 mRNA levels; (C) Nqo1 mRNA levels. (D) 
mRNA levels of ATF3 were analysed in both hTERT-HSC and primary HSC after expo-
sure to 1 ng/mL TGF-β1 for 48 hours. Fold induction were calculated as 2^(-ΔΔCT) for 
each sample and control and expressed as mean fold induction ± SD (N = 3 for hTERT-
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11. Lamlé J, Marhenke S, Borlak J, von Wasielewski R, Eriksson CJP, Geffers R, et al. Nuclear factor- 
eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology. 
2008; 134: 1159–1168. https://doi.org/10.1053/j.gastro.2008.01.011 PMID: 18395094 
12. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, Yamamoto M. Hepatocyte-
specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute 
drug toxicity. Bio- chem Biophys Res Commun. 2006; 339: 79–88. 
https://doi.org/10.1016/j.bbrc.2005.10.185 PMID: 16293230 
13. Goldring CEP, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, et al. Activa-
tion of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatol Baltim Md. 2004; 39: 1267–
1276. https:// doi.org/10.1002/hep.20183 PMID: 15122755 
14. Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, et al. Impaired liver regenera-
tion in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J. 2008; 
27: 212–223. https://doi.org/10.1038/sj.emboj.7601950 PMID: 18059474 
15. Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak M- K, et al. Regula-
tion of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal. 2010; 3: ra52. 
https://doi.org/ 10.1126/scisignal.2000762 PMID: 20628156 
16. Prestigiacomo V, Weston A, Messner S, Lampart F, Suter-Dick L. Pro-fibrotic compounds induce 
stel- late cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model 
of liver fibro- sis. PLOS ONE. 2017; 12: e0179995. https://doi.org/10.1371/journal.pone.0179995 
PMID: 28665955 
17. Oh CJ, Kim J-Y, Min A-K, Park K-G, Harris RA, Kim H-J, et al. Sulforaphane attenuates hepatic fibrosis 
via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. Free 
Radic Biol Med. 2012; 52: 671–682. https://doi.org/10.1016/j.freeradbiomed.2011.11.012 PMID: 
22155056 
18. Artaud-Macari E, Goven D, Brayer S, Hamimi A, Besnard V, Marchal-Somme J, et al. Nuclear 
factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation 
in idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2013; 18: 66–79. 
https://doi.org/10.1089/ars.2011.4240 PMID: 22703534 
19. Ryoo I, Ha H, Kwak M-K. Inhibitory Role of the KEAP1-NRF2 Pathway in TGFβ1-Stimulated Re-
nal Epi- thelial Transition to Fibroblastic Cells: A Modulatory Effect on SMAD Signaling. PLOS 
ONE. 2014; 9: e93265. https://doi.org/10.1371/journal.pone.0093265 PMID: 24691097 
20. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of acti-
vated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibro-
genic pheno- type. Hepatol Baltim Md. 2003; 37: 653–664. 
https://doi.org/10.1053/jhep.2003.50097 PMID: 12601363  
21. Hauck PM, Wolf ER, Olivos DJ, Batuello CN, McElyea KC, McAtarsney CP, et al. Early-Stage 
Metasta- sis Requires Mdm2 and Not p53 Gain of Function. Mol Cancer Res. 2017; 
https://doi.org/10.1158/1541- 7786.MCR-17-0174 PMID: 28784612 
22. Pennock R, Bray E, Pryor P, James S, McKeegan P, Sturmey R, et al. Human cell dedifferentia-
tion in mesenchymal condensates through controlled autophagy. Sci Rep. 2015; 5: 13113. 
https://doi.org/10. 1038/srep13113 PMID: 26290392 
 
 
Nrf2 role in hepatic stellate cells 







23. Li H-Y, Ju D, Zhang D-W, Li H, Kong L-M, Guo Y, et al. Activation of TGF-β1-CD147 positive 
feedback loop in hepatic stellate cells promotes liver fibrosis. Sci Rep. 2015; 5: 16552. 
https://doi.org/10.1038/ srep16552 PMID: 26559755 
24. Bakin AV, Stourman NV, Sekhar KR, Rinehart C, Yan X, Meredith MJ, et al. Smad3–ATF3 sig-
naling mediates TGF-β suppression of genes encoding Phase II detoxifying proteins. Free 
Radic Biol Med. 2005; 38: 375–387. https://doi.org/10.1016/j.freeradbiomed.2004.10.033 
PMID: 15629866 
25. Brown SL, Sekhar KR, Rachakonda G, Sasi S, Freeman ML. Activating Transcription Factor 3 Is a 
Novel Repressor of the Nuclear Factor Erythroid-Derived 2–Related Factor 2 (Nrf2)–Regulated 
Stress Pathway. Cancer Res. 2008; 68: 364–368. https://doi.org/10.1158/0008-5472.CAN-07-2170 
PMID: 18199529 
26. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor 
recep- tor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest. 
1994; 94: 1563– 1569. https://doi.org/10.1172/JCI117497 PMID: 7929832 
27. Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, et al. In-
creased Cell Migration and Plasticity in Nrf2 Deficient Cancer Cell Lines. Oncogene. 2010; 29: 
3703–3714. https:// doi.org/10.1038/onc.2010.118 PMID: 20440267 
28. Chien M-H, Lee W-J, Hsieh F-K, Li C-F, Cheng T-Y, Wang M-Y, et al. Keap1–Nrf2 Interaction 
Sup- presses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein. Clin Cancer 
Res. 2015; 21: 4719–4732. https://doi.org/10.1158/1078-0432.CCR-14-2880 PMID: 26078391 
29. Shen H, Yang Y, Xia S, Rao B, Zhang J, Wang J. Blockage of Nrf2 suppresses the migration and 
inva- sion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Eso-
phagus. 2014; 27: 685–692. https://doi.org/10.1111/dote.12124 PMID: 24028437 
30. Fan Z, Wirth A-K, Chen D, Wruck CJ, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway pro-
motes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017; 6: e371. 
https://doi.org/10.1038/oncsis. 2017.65 PMID: 28805788 
31. Murakami S, Motohashi H. Roles of Nrf2 in cell proliferation and differentiation. Free Radic Biol 
Med. 2015; 88, Part B: 168–178. https://doi.org/10.1016/j.freeradbiomed.2015.06.030 PMID: 
26119783 
32. Potteti HR, Tamatam CR, Marreddy R, Reddy NM, Noel S, Rabb H, et al. Nrf2-AKT interactions 
regu- late heme oxygenase 1 expression in kidney epithelia during hypoxia and hypoxia-reoxy-
genation. Am J Physiol Renal Physiol. 2016; 311: F1025–F1034. 
https://doi.org/10.1152/ajprenal.00362.2016 PMID: 27582105 
33. Cuadrado A, Mart´ın-Moldes Z, Ye J, Lastres-Becker I. Transcription Factors NRF2 and NF-κB 
Are Coordinated Effectors of the Rho Family, GTP-binding Protein RAC1 during Inflammation. J 
Biol Chem. 2014; 289: 15244–15258. https://doi.org/10.1074/jbc.M113.540633 PMID: 
24759106 
34. Cai CX, Buddha H, Castelino-Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of 
Insulin- PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonal-
coholic Steatohepa- titis. Dig Dis Sci. 2017; 62: 968–978. https://doi.org/10.1007/s10620-017-
4470-9 PMID: 28194671 
35. Wang Y, Jiang X-Y, Liu L, Jiang H-Q. Phosphatidylinositol 3-kinase/Akt pathway regulates hepatic 
stel- late cell apoptosis. World J Gastroenterol WJG. 2008; 14: 5186–5191. 
https://doi.org/10.3748/wjg.14. 5186 PMID: 18777595 
36. Churchman AT, Anwar AA, Li FYL, Sato H, Ishii T, Mann GE, et al. Transforming growth factor-
beta1 elicits Nrf2-mediated antioxidant responses in aortic smooth muscle cells. J Cell Mol 
Med. 2009; 13: 2282–2292. https://doi.org/10.1111/j.1582-4934.2009.00874.x PMID: 
19674192 
37. Okita Y, Kamoshida A, Suzuki H, Itoh K, Motohashi H, Igarashi K, et al. Transforming growth fac-
tor-β induces transcription factors MafK and Bach1 to suppress expression of the heme oxygen-
ase-1 gene. J Biol Chem. 2013; 288: 20658–20667. https://doi.org/10.1074/jbc.M113.450478 
PMID: 23737527 
38. Robson CN, Gnanapragasam V, Byrne RL, Collins AT, Neal DE. Transforming growth factor-
beta1 up- regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. 
J Endocrinol. 1999; 160: 257–266. PMID: 9924195 
39. Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC, Derynck R. Physical and Func-
tional Interactions between Type I Transforming Growth Factor β Receptors and Bα, a WD-40 
Repeat Subunit of Phosphatase 2A. Mol Cell Biol. 1998; 18: 6595–6604. PMID: 9774674 
40. Bataille AM, Manautou JE. Nrf2: a potential target for new therapeutics in liver disease. Clin Phar-
macol Ther. 2012; 92: 340–348. https://doi.org/10.1038/clpt.2012.110 PMID: 22871994 
41. Lin X, Duan X, Liang Y-Y, Su Y, Wrighton KH, Long J, et al. PPM1A functions as a Smad 
phosphatase to terminate TGFbeta signaling. Cell. 2006; 125: 915-928. 






Nrf2 role in hepatic stellate cells 







42. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, et al. Inhibition of Trans-
forming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β 
Type I Recep- tor Kinase Activity: SB-431542. Mol Pharmacol. 2002; 62: 58–64. 
https://doi.org/10.1124/mol.62.1.58 PMID: 12065755 
43. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 Is a Potent 
and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like 
Kinase (ALK) Receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002; 62: 65–74. 
https://doi.org/10.1124/ mol.62.1.65 PMID: 12065756 
44. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, et al. Inhibition of gene 
markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase 





In this chapter, a deep characterization of HSC activation has been presented. Particularly, the 
first paper (Prestigiacomo et al., under review 2018) aimed to elucidate the role of PDGF and 
TGF-β1 on HSC activation. Both primary and hTERT-HSC were characterized in terms of their 
activation, proliferative and migratory capacities. Upon exposure to TGF-β1, HSCs transdifferen-
tiated into myofibroblasts-like cells, showing strong production of αSMA and increase expression 
of Lox genes, collagens, and other ECM components (such as fibronectin and MMP2). A suc-
cessful inhibition of this fibrogenic effect of TGF-β1 was achieved by using Smad inhibitors 
(SB431542 hydrate and SB525334), confirming the role of TGF-β1/Smad pathway on HSC acti-
vation. The data show that similar mechanisms are valid in vitro in primary HSCs as well as in 
hTERT-HSCs. TGF-β1 also significantly decreased the proliferation rate of hTERT-HSC in a con-
centration-dependent manner, suggesting an involvement of Non-Smad pathways in the regula-
tion of HSC proliferation as previously reported for epithelial cells [133]. In contrast, PDGF-treat-
ment induced proliferation and cell migration in a concentration-dependent manner without elicit-
ing activation and fibrogenesis. Simultaneous exposure of HSCs to both compounds showed a 
synergistic effect leading to a myofibroblasts-like phenotype of activated HSC, which show in-
crease in αSMA amount, ECM deposition, and migration. Furthermore, these data show that 
hTERT-HSC react likewise primary HSC, identifying them as a well-suited surrogated of primary 
HSCs for activation studies in vitro. This study elucidates the effect of these two relevant cytokines 
on key aspects that characterize HSC activation, making clear that both factors are essential to 
achieve a fully activated phenotype in vitro. 
The second and main study carried out on this chapter (Prestigiacomo V and Suter-Dick L, PLoS 
ONE 2018) describes a novel and crucial role of Nrf2 in HSCs. Nrf2 was found to be highly ex-
pressed in quiescent HSCs, where it may contribute to the maintaining of a repressed phenotype. 
Nrf2 stabilization, achieved by means of Keap1 knockdown, significantly reduced the TGF-β1-
induced αSMA production, suggesting a protective role of Nrf2 against HSC activation. Consist-
ently, Nrf2 knockdown induced HSC activation in both primary and immortalised HSCs, as shown 
by the increase in αSMA production as well as the induction of gene expression of ECM compo-
nents (collagens and fibronectin). Hence, Nrf2 is shown not only to act as a protective molecule 
against ROS but also as a repressive factor for HSC activation. In addition, the Nrf2 knockdown-
induced HSC activation indicated an involvement of the TGF-β1/Smad pathway. In particular, we 
observed that Nrf2 depletion induced TGF-β1 release and Smad-dependent HSC activation, as 
suggested by the successful inhibition with Smad inhibitors (SB431542 hydrate and SB525334). 
Moreover, Nrf2 knockdown exacerbated the TGF-β1-induced activation as indicated by the 
stronger gene induction of fibrotic and activation markers. These data led to the identification of 
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Nrf2 as a “safeguard” of HSCs, and its depletion may be a contributing factor to HSC activation 
and fibrosis progression.  
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 Scientific impact, limitations and future perspectives of current 
research 
The research carried out during this thesis addressed some limiting factors, which are faced when 
attempting to study liver fibrotic diseases. These limitations include the lack of a suitable 3D model 
as well as the scarcity of therapeutic intervention able to revert HSC activation and restore liver 
homeostasis during fibrosis. Therefore, the aim of the first two studies was the development of a 
rat primary cell-based and a human cell line-based liver model. While the other two studies aimed 
at elucidating the molecular mechanisms behind HSC activation, focusing in particular on the 
interplay of PDGF and TGF-β1 and on the potential role of Nrf2. The 3D model systems developed 
in these studies were able to recapitulate the cellular events leading to fibrosis: hepatocellular 
injury, antioxidant defence response, activation of Kupffer cells and activation of HSC leading to 
deposition of ECM. The rat model generated included the three relevant cell types involved in 
fibrosis and was able to elicit a fibrotic phenotype after exposure to TGF-β1. Moreover, the human 
cell line-based model showed the ability to physiologically respond to pro-fibrotic drugs, indicating 
this system as a suitable model to study liver injury disease induced by clinically relevant com-
pounds. The cell line-based model also represents a suited alternative to human primary cell-
based models, due to the stability and easy handling of cell lines compared to primary cells. How-
ever, although these models hold a large amount of potential, an analogous model with human 
primary cells may be required to corroborate the data obtained. Moreover, the lack of LSEC rep-
resent another key limitation of these models. Although the LSECs are not the primary effectors 
of liver fibrosis, there is growing evidence that they play modulatory effects. Future developments 
to further improve and validate the system should aim at including LSECs, as well as at testing 
other liver toxicants (e.g. acetaminophen, bile acids or lipid overloading) and/or at using a micro-
fluidic design that may give an additional increment to the reliability of the model. Thereafter, the 
system may be used for the detection of potential pro-fibrotic compounds and for replacing used 
animal models. It may also allow testing of anti-fibrotic compounds in a physiological relevant in 
vitro system, providing researchers a novel tool to study inhibition of fibrosis progression.  
In addition to the development of a suitable in vitro model, this thesis also addressed specific 
mechanisms involved in the activation of HSCs. In particular, we aimed to further characterize 
HSC activation following exposure to PDGF and TGF-β1. Our data confirmed the involvement of 
these cytokines in the activation of HSCs and provided additional evidence supporting the hy-
pothesis that both signals act synergistically during HSCs activation. The results also indicated 
that both cytokines are required in order to elicit a complete activated phenotype in HSCs. Mech-
anistic in vivo and in vitro studies are required to better understand the potential interconnection 
between these two pathways. Future research should include studies with inhibitors of the PDGF 
pathway that may be useful to characterize the cascade of events occurring after PDGF signal-
ling. Furthermore, the results presented on both human primary and immortalised HSCs point out 
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the hTERT-HSC as a reliable cell line to further investigate these pathways, and represents a 
more accessible model than primary HSCs. 
Both primary and hTERT-HSCs were also utilized to investigate the role of Nrf2 in HSC activation. 
The most exciting result of this research was the identification of Nrf2 as a crucial protective factor 
against HSC activation. We could show that Nrf2 inhibits HSC activation acting through the inhi-
bition of the TGF-β1/Smad pathway. Additional studies are required to evaluate its potential in-
terference with Non-Smad pathway as well as PDGF regulation pathway. Nevertheless, our data 
suggest that an intervention on Nrf2 pathway in HSC may be a new therapeutic approach for the 
prevention and/or reduction of HSC activation. An additional line of investigation that might be 
pursued in light of our results is the study of the involvement of Nrf2 in fibrosis using the multicel-
lular, 3D culture model. Nrf2 has already been shown to promote liver regeneration and hepato-
cyte growth [78,79], so together with the data obtained in the current research, a strategy aiming 
to Nrf2 induction and/or stabilization may result in a safer and effective therapy to heal fibrotic 
diseases. 
In conclusion, the studies presented in this thesis provide encouraging data that may contribute 
to the design and the identification of novel therapeutic approach for liver fibrosis. The 3D liver 
models here generated may give a pulse to study fibrosis development and to test novel drugs, 
in order to consolidate in vivo data in an inexpensive and productive way. Furthermore, the newly 
found role of the Nrf2 defence pathway in HSCs, together with the well-known role it plays in 
hepatocytes, may boost the research on liver towards a therapeutic strategy based on the stimu-
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